{"docstore/data": {"415b6f71-dfce-48b2-9d09-886ac60be37d": {"__data__": {"id_": "415b6f71-dfce-48b2-9d09-886ac60be37d", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "16", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "51d87c3c415473635871db92d77539c97f27841981981b78dd37e82215848eba", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "4d7a83cf-6818-4995-b087-c6500328b6cc", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "019751c8d2f302ca857042d6b00d58cb890adc18f000afac3fd8ca9f6fc70f74", "class_name": "RelatedNodeInfo"}, {"node_id": "75545837-636f-40fb-a3ba-7d32cd53b7a8", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "2c6f2354dcdea396f0338ba1d28914ab25a595fdfb3f942c508f4158e4029a34", "class_name": "RelatedNodeInfo"}, {"node_id": "2191927a-5564-4bfe-ac51-fdef7371c820", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "0502ea6b6131ee9dc22dcb9d89103b19969a23f42fee277691867732444b5485", "class_name": "RelatedNodeInfo"}, {"node_id": "9165a3ad-f0ac-4d02-b76e-7b2ad6075a39", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "6fa19094be05570294b7d91839e73dca4d275cd56deaf055a7af02ee10919a2d", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "3\n. \nUesugi M et al. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in\nliving-donor liver transplantation. Pharmacogenet Genomics 2014;24:356-66.\n4\n. \nTerrazzino S et al. The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute\nrejection rates in renal transplant patients: a systematic review and meta-analysis. Pharmacogenet Genomics 2012;22:642-5.\n5\n. \nTang HL et al. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 non-expressers than expressers.\nPharmacogenet Genomics 2011;21:713-20.\n6\n. \nJacobson PA et al. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney\ntransplant consortium. Transplantation 2011;91:300-8.\n7\n. \nThervet E et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 2010; 87: 721-726.\n8\n. \nSatoh S et al. Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages\nin Japanese renal transplant recipients. Br J Clin Pharmacol 2008;66:207-14.\n9\n. \nKlauke B et al. No association between single nucleotide polymorphisms and the development of nephrotoxicity after orthotopic\nheart transplantation. J Heart Lung Transplant 2008;27:741-5.\n10\n. \nFukudo M et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in\nadult living-donor liver transplant patients. Pharmacogenet Genomics 2008;18:413-23.\n11\n. \nHesselink DA et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant\nrecipients. Pharmacogenet Genomics 2008;18:339-48.\n12\n. \nKuypers DR et al. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus\ndisposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007;82:711-25.\n13\n. \nRenders L et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant\nrecipients. Clin Pharmacol Ther 2007;81:228-34.\n14\n. \nMourad M et al. The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-\nstandardized tacrolimus trough concentrations after kidney transplantation in relation to renal function. Clin Chem Lab Med\n2006;44:1192-8.\n15\n. \nRoy JN et al. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.\nPharmacogenet Genomics 2006;16:659-65.\n16\n. \nCheung CY et al. Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic\nprofile of Chinese renal transplant recipients. Pharmacogenomics 2006;7:563-74.\n17\n. \nUesugi M et al. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients.\nPharmacogenet Genomics 2006;16:119-27.\n18\n. \nZhang X et al. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal\ntransplantation. Clin Transplant 2005;19:638-43.\n19\n. \nTada H et al. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal\ntransplant recipients. Transplant Proc 2005;37:1730-2.\n20\n. \nMacphee IA et al. Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood\nconcentrations in whites and South Asians. Transplantation 2005;79:499-502.\n21\n. \nHesselink DA et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin\ninhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003;74:245-54.\nDate 09-11-2015\nCYP2D6 IM: tamoxifen\n1602\nThis gene variation reduces the conversion of tamoxifen to the active metabolite endoxifen. This can result in reduced effectiveness.\nRecommendation:\n1\n. \nselect an alternative or measure the endoxifen concentration and increase the dose if necessary by a factor of 1.5-2\nAromatase inhibitors are a possible alternative for post-menopausal women.\n2\n. \nif TAMOXIFEN is selected: avoid co-medication with CYP2D6 inhibitors such as paroxetine and fluoxetine\nLiterature:\n1\n. \nWelzen ME et al. The effect of tamoxifen dose increment in patients with impaired CYP2D6 activity. Ther Drug Monit\n2015;37:501-7.\n2\n. \nMartinez de Due\u00f1as E et al. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer\nphenotype. Breast 2014;23:400-6.\n3\n. \nProvince MA et al. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol\nTher 2014;95:216-27.\n4\n. \nJung JA et al. Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-\nanalysis. Pharmacogenomics2014;15:49-60.\n5\n. \nCronin-Fenton DP et al. Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 4953, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4d7a83cf-6818-4995-b087-c6500328b6cc": {"__data__": {"id_": "4d7a83cf-6818-4995-b087-c6500328b6cc", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "16", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "51d87c3c415473635871db92d77539c97f27841981981b78dd37e82215848eba", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "415b6f71-dfce-48b2-9d09-886ac60be37d", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "12e2f65a49709251a0f19efb2fe46940a9b61462ad30bb506ebc5160ccd4651c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "3\n. \nUesugi M et al. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in\nliving-donor liver transplantation. Pharmacogenet Genomics 2014;24:356-66.\n4\n. \nTerrazzino S et al. The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute\nrejection rates in renal transplant patients: a systematic review and meta-analysis. Pharmacogenet Genomics 2012;22:642-5.\n5\n. \nTang HL et al. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 non-expressers than expressers.\nPharmacogenet Genomics 2011;21:713-20.\n6\n. \nJacobson PA et al. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney\ntransplant consortium. Transplantation 2011;91:300-8.\n7\n. \nThervet E et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 2010; 87: 721-726.\n8\n. \nSatoh S et al. Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages\nin Japanese renal transplant recipients. Br J Clin Pharmacol 2008;66:207-14.\n9\n. \nKlauke B et al. No association between single nucleotide polymorphisms and the development of nephrotoxicity after orthotopic\nheart transplantation. J Heart Lung Transplant 2008;27:741-5.\n10\n. \nFukudo M et al.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1357, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "75545837-636f-40fb-a3ba-7d32cd53b7a8": {"__data__": {"id_": "75545837-636f-40fb-a3ba-7d32cd53b7a8", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "16", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "51d87c3c415473635871db92d77539c97f27841981981b78dd37e82215848eba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d7a83cf-6818-4995-b087-c6500328b6cc", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "019751c8d2f302ca857042d6b00d58cb890adc18f000afac3fd8ca9f6fc70f74", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "415b6f71-dfce-48b2-9d09-886ac60be37d", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "12e2f65a49709251a0f19efb2fe46940a9b61462ad30bb506ebc5160ccd4651c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "10\n. \nFukudo M et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in\nadult living-donor liver transplant patients. Pharmacogenet Genomics 2008;18:413-23.\n11\n. \nHesselink DA et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant\nrecipients. Pharmacogenet Genomics 2008;18:339-48.\n12\n. \nKuypers DR et al. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus\ndisposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007;82:711-25.\n13\n. \nRenders L et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant\nrecipients. Clin Pharmacol Ther 2007;81:228-34.\n14\n. \nMourad M et al. The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-\nstandardized tacrolimus trough concentrations after kidney transplantation in relation to renal function. Clin Chem Lab Med\n2006;44:1192-8.\n15\n. \nRoy JN et al. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.\nPharmacogenet Genomics 2006;16:659-65.\n16\n. \nCheung CY et al. Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic\nprofile of Chinese renal transplant recipients. Pharmacogenomics 2006;7:563-74.\n17\n.", "mimetype": "text/plain", "start_char_idx": 1336, "end_char_idx": 2774, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2191927a-5564-4bfe-ac51-fdef7371c820": {"__data__": {"id_": "2191927a-5564-4bfe-ac51-fdef7371c820", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "16", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "51d87c3c415473635871db92d77539c97f27841981981b78dd37e82215848eba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75545837-636f-40fb-a3ba-7d32cd53b7a8", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "2c6f2354dcdea396f0338ba1d28914ab25a595fdfb3f942c508f4158e4029a34", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "415b6f71-dfce-48b2-9d09-886ac60be37d", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "12e2f65a49709251a0f19efb2fe46940a9b61462ad30bb506ebc5160ccd4651c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Pharmacogenomics 2006;7:563-74.\n17\n. \nUesugi M et al. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients.\nPharmacogenet Genomics 2006;16:119-27.\n18\n. \nZhang X et al. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal\ntransplantation. Clin Transplant 2005;19:638-43.\n19\n. \nTada H et al. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal\ntransplant recipients. Transplant Proc 2005;37:1730-2.\n20\n. \nMacphee IA et al. Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood\nconcentrations in whites and South Asians. Transplantation 2005;79:499-502.\n21\n. \nHesselink DA et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin\ninhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003;74:245-54.\nDate 09-11-2015\nCYP2D6 IM: tamoxifen\n1602\nThis gene variation reduces the conversion of tamoxifen to the active metabolite endoxifen. This can result in reduced effectiveness.\nRecommendation:\n1\n. \nselect an alternative or measure the endoxifen concentration and increase the dose if necessary by a factor of 1.5-2\nAromatase inhibitors are a possible alternative for post-menopausal women.\n2\n.", "mimetype": "text/plain", "start_char_idx": 2738, "end_char_idx": 4084, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9165a3ad-f0ac-4d02-b76e-7b2ad6075a39": {"__data__": {"id_": "9165a3ad-f0ac-4d02-b76e-7b2ad6075a39", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "16", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "51d87c3c415473635871db92d77539c97f27841981981b78dd37e82215848eba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2191927a-5564-4bfe-ac51-fdef7371c820", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "0502ea6b6131ee9dc22dcb9d89103b19969a23f42fee277691867732444b5485", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "415b6f71-dfce-48b2-9d09-886ac60be37d", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "12e2f65a49709251a0f19efb2fe46940a9b61462ad30bb506ebc5160ccd4651c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "2\n. \nif TAMOXIFEN is selected: avoid co-medication with CYP2D6 inhibitors such as paroxetine and fluoxetine\nLiterature:\n1\n. \nWelzen ME et al. The effect of tamoxifen dose increment in patients with impaired CYP2D6 activity. Ther Drug Monit\n2015;37:501-7.\n2\n. \nMartinez de Due\u00f1as E et al. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer\nphenotype. Breast 2014;23:400-6.\n3\n. \nProvince MA et al. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol\nTher 2014;95:216-27.\n4\n. \nJung JA et al. Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-\nanalysis. Pharmacogenomics2014;15:49-60.\n5\n. \nCronin-Fenton DP et al. Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing", "mimetype": "text/plain", "start_char_idx": 4081, "end_char_idx": 4953, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "03b486a0-1625-4a09-b986-23c46f1ac0f4": {"__data__": {"id_": "03b486a0-1625-4a09-b986-23c46f1ac0f4", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "8bf540cd70fb2da653b51de0fe335ce7d93cdeccd8219280646176ffcbf9693c", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "14461f29-2cc7-4f93-8f5a-49fc29f2c123", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "d1aacfb28e44e702b346507f0402f4a53fd97eb16552c76a1f675c0748151260", "class_name": "RelatedNodeInfo"}, {"node_id": "708ee684-e806-4b65-88d2-8c3e0ff2fc11", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "a183eaa04f1d3716dc8d306b7f11507ae8ae2da643d40330a0815a02c1cda5fb", "class_name": "RelatedNodeInfo"}, {"node_id": "08aa4462-cd86-4356-b37e-35ac92814ae6", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "884ac6e5963457f3a8ea03ca6d5f84f1aac5a2e1297eca6d6814d6a973000595", "class_name": "RelatedNodeInfo"}, {"node_id": "3a6c6024-87dc-4714-9e0d-29dfe3921274", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "8537ae12299429590fb43d89e07c27193d4f9d698f8421632a90d2b7b941e871", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "controversy. Future Oncol 2014;10:107-22.\n6\n. \nLum DW et al. CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis. PLoS One\n2013;8:e76648.\n7\n. \nZeng Z et al. CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis. Cancer\nChemother Pharmacol 2013;72:287-303.\n8\n. \nRegan MM et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer:\nthe breast international group 1-98 trial. J Natl Cancer Inst 2012;104:441-51.\n9\n. \nRae JM et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer\nInst 2012;104:452-60.\n10\n. \nPark IH et al. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early\nbreast cancer patients receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2012;131:455-61.\n11\n. \nKiyotani K et al. Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. Breast\nCancer Res Treat 2012;131:137-45.\n12\n. \nBarginear MF et al. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect\non active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Ther 2011;90:605-11.\n13\n. \nIrvin WJ Jr et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6\nmetabolism: a multicenter study. J Clin Oncol 2011;29:3232-9.\n14\n. \nLash TL et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst\n2011;103:489-500.\n15\n. \nThompson AM et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with\ntamoxifen monotherapy. Breast Cancer Res Treat 2011;125:279-87.\n16\n. \nStingl JC et al. Impact of CYP2D6 *4 genotype on progression free survival in tamoxifen breast cancer treatment. Curr Med Res\nOpin 2010;26:2535-42.\n17\n. \nLammers LA et al. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast\ncancer. Br J Cancer 2010;103:765-71.\n18\n. \nSchroth W et al. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded\npolymorphism coverage improves risk stratification. Clin Cancer Res 2010;16:4468-77.\n19\n. \nSeruga B et al. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Res\nTreat 2010;122:609-17.\n20\n. \nKiyotani K et al. Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response.\nPharmacogenet Genomics 2010;20:565-8.\n21\n. \nAbraham JE et al. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients\nfrom the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 2010;12:R64.\n22\n. \nSchroth W et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated\nwith tamoxifen. JAMA 2009;302:1429-36.\n23\n. \nGjerde J et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.\nAnn Oncol 2008;19:56-61.\n24\n. \nSchroth W et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J\nClin Oncol 2007;25:5187-93.\n25\n. \nLim HS et al. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J\nClin Oncol 2007;25:3837-45.\n26\n. \nGonzalez-Santiago S et al. CYP2D6*4 polymorphism as blood predictive biomarker of breast cancer relapse in patients receiving\nadjuvant tamoxifen. J Clin Oncol 2007;25(18S):590.\n27\n. \nWegman P et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal\npatients with breast cancer. Breast Cancer Res 2007;9:R7.\n28\n. \nGoetz MP et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res\nTreat 2007;101:113-21.\n29\n. \nBorges S et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of\nbreast cancer treatment. Clin Pharmacol Ther 2006;80:61-74.\n30\n. \nNowell SA et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of\ndisease in breast cancer patients. Breast Cancer Res Treat 2005;91:249-58.\n31\n. \nJin Y et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl\nCancer Inst 2005;97:30-9.\n32\n. \nWegman P et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast\nCancer Res 2005;7:R284-90.\nDate 09-11-2015\nCYP2D6 PM: tamoxifen\n1601\nThis gene variation reduces the conversion of tamoxifen to the active metabolite endoxifen. This can result in reduced effectiveness.\nRecommendation:\n1\n. \nselect an alternative or increase the dose to 40 mg/day and monitor the endoxifen concentration\nStudies have demonstrated that PM can achieve an adequate endoxifen concentration when the dose is increased to 40-60 mg/day.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 5198, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "14461f29-2cc7-4f93-8f5a-49fc29f2c123": {"__data__": {"id_": "14461f29-2cc7-4f93-8f5a-49fc29f2c123", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "8bf540cd70fb2da653b51de0fe335ce7d93cdeccd8219280646176ffcbf9693c", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "03b486a0-1625-4a09-b986-23c46f1ac0f4", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "6b2699f9dda99389b5dc834f678e0bd7b335e4b9e845b8cbd254ceb8eab3dc53", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "controversy. Future Oncol 2014;10:107-22.\n6\n. \nLum DW et al. CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis. PLoS One\n2013;8:e76648.\n7\n. \nZeng Z et al. CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis. Cancer\nChemother Pharmacol 2013;72:287-303.\n8\n. \nRegan MM et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer:\nthe breast international group 1-98 trial. J Natl Cancer Inst 2012;104:441-51.\n9\n. \nRae JM et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer\nInst 2012;104:452-60.\n10\n. \nPark IH et al. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early\nbreast cancer patients receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2012;131:455-61.\n11\n. \nKiyotani K et al. Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. Breast\nCancer Res Treat 2012;131:137-45.\n12\n. \nBarginear MF et al. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect\non active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Ther 2011;90:605-11.\n13\n. \nIrvin WJ Jr et al.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1360, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "708ee684-e806-4b65-88d2-8c3e0ff2fc11": {"__data__": {"id_": "708ee684-e806-4b65-88d2-8c3e0ff2fc11", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "8bf540cd70fb2da653b51de0fe335ce7d93cdeccd8219280646176ffcbf9693c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14461f29-2cc7-4f93-8f5a-49fc29f2c123", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "d1aacfb28e44e702b346507f0402f4a53fd97eb16552c76a1f675c0748151260", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "03b486a0-1625-4a09-b986-23c46f1ac0f4", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "6b2699f9dda99389b5dc834f678e0bd7b335e4b9e845b8cbd254ceb8eab3dc53", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "13\n. \nIrvin WJ Jr et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6\nmetabolism: a multicenter study. J Clin Oncol 2011;29:3232-9.\n14\n. \nLash TL et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst\n2011;103:489-500.\n15\n. \nThompson AM et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with\ntamoxifen monotherapy. Breast Cancer Res Treat 2011;125:279-87.\n16\n. \nStingl JC et al. Impact of CYP2D6 *4 genotype on progression free survival in tamoxifen breast cancer treatment. Curr Med Res\nOpin 2010;26:2535-42.\n17\n. \nLammers LA et al. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast\ncancer. Br J Cancer 2010;103:765-71.\n18\n. \nSchroth W et al. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded\npolymorphism coverage improves risk stratification. Clin Cancer Res 2010;16:4468-77.\n19\n. \nSeruga B et al. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Res\nTreat 2010;122:609-17.\n20\n. \nKiyotani K et al. Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response.\nPharmacogenet Genomics 2010;20:565-8.\n21\n. \nAbraham JE et al.", "mimetype": "text/plain", "start_char_idx": 1336, "end_char_idx": 2733, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "08aa4462-cd86-4356-b37e-35ac92814ae6": {"__data__": {"id_": "08aa4462-cd86-4356-b37e-35ac92814ae6", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "8bf540cd70fb2da653b51de0fe335ce7d93cdeccd8219280646176ffcbf9693c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "708ee684-e806-4b65-88d2-8c3e0ff2fc11", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "a183eaa04f1d3716dc8d306b7f11507ae8ae2da643d40330a0815a02c1cda5fb", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "03b486a0-1625-4a09-b986-23c46f1ac0f4", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "6b2699f9dda99389b5dc834f678e0bd7b335e4b9e845b8cbd254ceb8eab3dc53", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "21\n. \nAbraham JE et al. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients\nfrom the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 2010;12:R64.\n22\n. \nSchroth W et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated\nwith tamoxifen. JAMA 2009;302:1429-36.\n23\n. \nGjerde J et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.\nAnn Oncol 2008;19:56-61.\n24\n. \nSchroth W et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J\nClin Oncol 2007;25:5187-93.\n25\n. \nLim HS et al. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J\nClin Oncol 2007;25:3837-45.\n26\n. \nGonzalez-Santiago S et al. CYP2D6*4 polymorphism as blood predictive biomarker of breast cancer relapse in patients receiving\nadjuvant tamoxifen. J Clin Oncol 2007;25(18S):590.\n27\n. \nWegman P et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal\npatients with breast cancer. Breast Cancer Res 2007;9:R7.\n28\n. \nGoetz MP et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.", "mimetype": "text/plain", "start_char_idx": 2710, "end_char_idx": 4028, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3a6c6024-87dc-4714-9e0d-29dfe3921274": {"__data__": {"id_": "3a6c6024-87dc-4714-9e0d-29dfe3921274", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "8bf540cd70fb2da653b51de0fe335ce7d93cdeccd8219280646176ffcbf9693c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08aa4462-cd86-4356-b37e-35ac92814ae6", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "884ac6e5963457f3a8ea03ca6d5f84f1aac5a2e1297eca6d6814d6a973000595", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "03b486a0-1625-4a09-b986-23c46f1ac0f4", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "6b2699f9dda99389b5dc834f678e0bd7b335e4b9e845b8cbd254ceb8eab3dc53", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Breast Cancer Res\nTreat 2007;101:113-21.\n29\n. \nBorges S et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of\nbreast cancer treatment. Clin Pharmacol Ther 2006;80:61-74.\n30\n. \nNowell SA et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of\ndisease in breast cancer patients. Breast Cancer Res Treat 2005;91:249-58.\n31\n. \nJin Y et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl\nCancer Inst 2005;97:30-9.\n32\n. \nWegman P et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast\nCancer Res 2005;7:R284-90.\nDate 09-11-2015\nCYP2D6 PM: tamoxifen\n1601\nThis gene variation reduces the conversion of tamoxifen to the active metabolite endoxifen. This can result in reduced effectiveness.\nRecommendation:\n1\n. \nselect an alternative or increase the dose to 40 mg/day and monitor the endoxifen concentration\nStudies have demonstrated that PM can achieve an adequate endoxifen concentration when the dose is increased to 40-60 mg/day.", "mimetype": "text/plain", "start_char_idx": 4029, "end_char_idx": 5198, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fb9a1a99-967f-4e87-818f-0321c337c788": {"__data__": {"id_": "fb9a1a99-967f-4e87-818f-0321c337c788", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "18", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "d7fcdd8c62bca1fc92737347bef938f756e9e77f2c90c4f02ca94d5751d8b8a2", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "04b88305-c67b-42a2-85b5-0b782f5b198c", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "861e5a42202db9cccfd65817c1b03f3d2eab3ed182121b0fa8dcaabb54a8deb4", "class_name": "RelatedNodeInfo"}, {"node_id": "6a701a8f-e6b0-4f8d-a3d7-6e35518d11b2", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "39e892fe7c6cc42b7ba804c5b1bc262372463518a27e0b1bd59d2cd8b426f244", "class_name": "RelatedNodeInfo"}, {"node_id": "a1d653d7-76c9-450c-83d5-b8cace8b2ba1", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "defeeb5c6452b495b75274981e0d0b81d1688585d09b8fb7d2a8699df15657c1", "class_name": "RelatedNodeInfo"}, {"node_id": "6113650c-69ea-45cf-916c-c1355374ff25", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "b1705f98ed4f3a519ecac2a738e337b4f09ed3cd677bd88e787a984257686929", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Aromatase inhibitors are a possible alternative for post-menopausal women.\nLiterature:\n1\n. \nWelzen ME et al. The effect of tamoxifen dose increment in patients with impaired CYP2D6 activity. Ther Drug Monit\n2015;37:501-7.\n2\n. \nMartinez de Due\u00f1as E et al. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer\nphenotype. Breast 2014;23:400-6.\n3\n. \nProvince MA et al. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol\nTher 2014;95:216-27.\n4\n. \nJung JA et al. Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-\nanalysis. Pharmacogenomics2014;15:49-60.\n5\n. \nCronin-Fenton DP et al. Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing\ncontroversy. Future Oncol 2014;10:107-22.\n6\n. \nLum DW et al. CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis. PLoS One\n2013;8:e76648.\n7\n. \nZeng Z et al. CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis. Cancer\nChemother Pharmacol 2013;72:287-303.\n8\n. \nRegan MM et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer:\nthe breast international group 1-98 trial. J Natl Cancer Inst 2012;104:441-51.\n9\n. \nRae JM et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer\nInst 2012;104:452-60.\n10\n. \nBarginear MF et al. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect\non active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Ther 2011;90:605-11.\n11\n. \nIrvin WJ Jr et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6\nmetabolism: a multicenter study. J Clin Oncol 2011;29:3232-9.\n12\n. \nLash TL et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst\n2011;103:489-500.\n13\n. \nThompson AM et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with\ntamoxifen monotherapy. Breast Cancer Res Treat 2011;125:279-87.\n14\n. \nStingl JC et al. Impact of CYP2D6 *4 genotype on progression free survival in tamoxifen breast cancer treatment. Curr Med Res\nOpin 2010;26:2535-42.\n15\n. \nLammers LA et al. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast\ncancer. Br J Cancer 2010;103:765-71.\n16\n. \nSchroth W et al. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded\npolymorphism coverage improves risk stratification. Clin Cancer Res 2010;16:4468-77.\n17\n. \nSeruga B et al. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Res\nTreat 2010;122:609-17.\n18\n. \nKiyotani K et al. Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response.\nPharmacogenet Genomics 2010;20:565-8.\n19\n. \nAbraham JE et al. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients\nfrom the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 2010;12:R64.\n20\n. \nSchroth W et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated\nwith tamoxifen. JAMA 2009;302:1429-36.\n21\n. \nGjerde J et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.\nAnn Oncol 2008;19:56-61.\n22\n. \nSchroth W et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J\nClin Oncol 2007;25:5187-93.\n23\n. \nGonzalez-Santiago S et al. CYP2D6*4 polymorphism as blood predictive biomarker of breast cancer relapse in patients receiving\nadjuvant tamoxifen. J Clin Oncol 2007;25(18S):590.\n24\n. \nWegman P et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal\npatients with breast cancer. Breast Cancer Res 2007;9:R7.\n25\n. \nGoetz MP et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res\nTreat 2007;101:113-21.\n26\n. \nBonanni B ea. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from\nthe Italian Tamoxifen Trial. J Clin Oncol 2006;24:3708-9.\n27\n. \nBorges S et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of\nbreast cancer treatment. Clin Pharmacol Ther 2006;80:61-74.\n28\n. \nGoetz MP et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.\nJ Clin Oncol 2005;23:9312-8.\n29\n. \nNowell SA et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of\ndisease in breast cancer patients. Breast Cancer Res Treat 2005;91:249-58.\n30\n. \nJin Y et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl\nCancer Inst 2005;97:30-9.\n31\n. \nWegman P et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 5390, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "04b88305-c67b-42a2-85b5-0b782f5b198c": {"__data__": {"id_": "04b88305-c67b-42a2-85b5-0b782f5b198c", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "18", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "d7fcdd8c62bca1fc92737347bef938f756e9e77f2c90c4f02ca94d5751d8b8a2", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "fb9a1a99-967f-4e87-818f-0321c337c788", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "27875d61e477656deefe5cf1d3b6bd2ed4a399b5474a0afdabe4e0f3c2e4e3cb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Aromatase inhibitors are a possible alternative for post-menopausal women.\nLiterature:\n1\n. \nWelzen ME et al. The effect of tamoxifen dose increment in patients with impaired CYP2D6 activity. Ther Drug Monit\n2015;37:501-7.\n2\n. \nMartinez de Due\u00f1as E et al. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer\nphenotype. Breast 2014;23:400-6.\n3\n. \nProvince MA et al. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol\nTher 2014;95:216-27.\n4\n. \nJung JA et al. Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-\nanalysis. Pharmacogenomics2014;15:49-60.\n5\n. \nCronin-Fenton DP et al. Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing\ncontroversy. Future Oncol 2014;10:107-22.\n6\n. \nLum DW et al. CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis. PLoS One\n2013;8:e76648.\n7\n. \nZeng Z et al. CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis. Cancer\nChemother Pharmacol 2013;72:287-303.\n8\n. \nRegan MM et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer:\nthe breast international group 1-98 trial. J Natl Cancer Inst 2012;104:441-51.\n9\n. \nRae JM et al.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1411, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6a701a8f-e6b0-4f8d-a3d7-6e35518d11b2": {"__data__": {"id_": "6a701a8f-e6b0-4f8d-a3d7-6e35518d11b2", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "18", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "d7fcdd8c62bca1fc92737347bef938f756e9e77f2c90c4f02ca94d5751d8b8a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04b88305-c67b-42a2-85b5-0b782f5b198c", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "861e5a42202db9cccfd65817c1b03f3d2eab3ed182121b0fa8dcaabb54a8deb4", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "fb9a1a99-967f-4e87-818f-0321c337c788", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "27875d61e477656deefe5cf1d3b6bd2ed4a399b5474a0afdabe4e0f3c2e4e3cb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "9\n. \nRae JM et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer\nInst 2012;104:452-60.\n10\n. \nBarginear MF et al. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect\non active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Ther 2011;90:605-11.\n11\n. \nIrvin WJ Jr et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6\nmetabolism: a multicenter study. J Clin Oncol 2011;29:3232-9.\n12\n. \nLash TL et al. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst\n2011;103:489-500.\n13\n. \nThompson AM et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with\ntamoxifen monotherapy. Breast Cancer Res Treat 2011;125:279-87.\n14\n. \nStingl JC et al. Impact of CYP2D6 *4 genotype on progression free survival in tamoxifen breast cancer treatment. Curr Med Res\nOpin 2010;26:2535-42.\n15\n. \nLammers LA et al. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast\ncancer. Br J Cancer 2010;103:765-71.\n16\n. \nSchroth W et al. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded\npolymorphism coverage improves risk stratification. Clin Cancer Res 2010;16:4468-77.", "mimetype": "text/plain", "start_char_idx": 1393, "end_char_idx": 2832, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a1d653d7-76c9-450c-83d5-b8cace8b2ba1": {"__data__": {"id_": "a1d653d7-76c9-450c-83d5-b8cace8b2ba1", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "18", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "d7fcdd8c62bca1fc92737347bef938f756e9e77f2c90c4f02ca94d5751d8b8a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a701a8f-e6b0-4f8d-a3d7-6e35518d11b2", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "39e892fe7c6cc42b7ba804c5b1bc262372463518a27e0b1bd59d2cd8b426f244", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "fb9a1a99-967f-4e87-818f-0321c337c788", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "27875d61e477656deefe5cf1d3b6bd2ed4a399b5474a0afdabe4e0f3c2e4e3cb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Clin Cancer Res 2010;16:4468-77.\n17\n. \nSeruga B et al. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Res\nTreat 2010;122:609-17.\n18\n. \nKiyotani K et al. Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response.\nPharmacogenet Genomics 2010;20:565-8.\n19\n. \nAbraham JE et al. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients\nfrom the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 2010;12:R64.\n20\n. \nSchroth W et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated\nwith tamoxifen. JAMA 2009;302:1429-36.\n21\n. \nGjerde J et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.\nAnn Oncol 2008;19:56-61.\n22\n. \nSchroth W et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J\nClin Oncol 2007;25:5187-93.\n23\n. \nGonzalez-Santiago S et al. CYP2D6*4 polymorphism as blood predictive biomarker of breast cancer relapse in patients receiving\nadjuvant tamoxifen. J Clin Oncol 2007;25(18S):590.\n24\n. \nWegman P et al.", "mimetype": "text/plain", "start_char_idx": 2800, "end_char_idx": 4052, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6113650c-69ea-45cf-916c-c1355374ff25": {"__data__": {"id_": "6113650c-69ea-45cf-916c-c1355374ff25", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "18", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "d7fcdd8c62bca1fc92737347bef938f756e9e77f2c90c4f02ca94d5751d8b8a2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1d653d7-76c9-450c-83d5-b8cace8b2ba1", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "defeeb5c6452b495b75274981e0d0b81d1688585d09b8fb7d2a8699df15657c1", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "fb9a1a99-967f-4e87-818f-0321c337c788", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "27875d61e477656deefe5cf1d3b6bd2ed4a399b5474a0afdabe4e0f3c2e4e3cb", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "24\n. \nWegman P et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal\npatients with breast cancer. Breast Cancer Res 2007;9:R7.\n25\n. \nGoetz MP et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res\nTreat 2007;101:113-21.\n26\n. \nBonanni B ea. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from\nthe Italian Tamoxifen Trial. J Clin Oncol 2006;24:3708-9.\n27\n. \nBorges S et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of\nbreast cancer treatment. Clin Pharmacol Ther 2006;80:61-74.\n28\n. \nGoetz MP et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.\nJ Clin Oncol 2005;23:9312-8.\n29\n. \nNowell SA et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of\ndisease in breast cancer patients. Breast Cancer Res Treat 2005;91:249-58.\n30\n. \nJin Y et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl\nCancer Inst 2005;97:30-9.\n31\n. \nWegman P et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast", "mimetype": "text/plain", "start_char_idx": 4031, "end_char_idx": 5390, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9c3f8a89-7eab-42f2-ad46-7eac6a5e8a5a": {"__data__": {"id_": "9c3f8a89-7eab-42f2-ad46-7eac6a5e8a5a", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 3, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 3, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "ac3e6c8d56c934b044824372f7b0dc62cc62cbd4a9f84952c311dd72536596b7", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "5012c871-a6d4-47f6-bd6c-74f4824a2b18", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 3, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "a46f935119d4d1ddf9d004b3f07cecb72b060dd167f4552bf1e7f2c3fcfcabd3", "class_name": "RelatedNodeInfo"}, {"node_id": "193ca1aa-5fdf-4adb-9fcc-f8ebe5e2ef23", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 3, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "b6aabc7b26b54124d6be0f7551597e08d06b59381ceee7dccd40526959936e18", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Cancer Res 2005;7:R284-90.\n32\n. \nSPC Tamoxifen PCH.\nDate 09-11-2015\nCYP2D6 UM: tamoxifen\n1603\nNO action is needed for this gene-drug interaction.\nAs a result of the genetic variation, the plasma concentration of the active metabolites 4-hydroxytamoxifen and endoxifen can increase.\nHowever, there is no evidence that this results in an increase in the side effects.\nLiterature:\n1\n. \nMartinez de Due\u00f1as E et al. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer\nphenotype. Breast 2014;23:400-6.\n2\n. \nSchroth W et al. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded\npolymorphism coverage improves risk stratification. Clin Cancer Res 2010;16:4468-77.\n3\n. \nGjerde J et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.\nAnn Oncol 2008;19:56-61.\n4\n. \nLim HS et al. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J\nClin Oncol 2007;25:3837-45.\nDate 09-11-2015\nDPD genact 0,5: tegafur\n4891\nGenetic variation increases the risk of severe, possibly fatal toxicity. A reduced conversion of tegafur to inactive metabolites means that\nthe normal dose is an overdose.\nRecommendation:\nChoose an alternative or start with a low dose and adjust the initial dose based on toxicity and efficacy\nFluorouracil and capecitabine are not alternatives, as these are also metabolised by DPD.\nIt is not possible to offer substantiated advice for dose reduction based on the literature. For fluorouracil and capecitabine, starting\nwith 25% of the standard dose is recommended.\nNOTE: This recommendation only applies if the two gene variations are on a different allele. If both variations are on the same\nallele, this patient has gene activity score 1 and the recommendation for that gene activity score should be followed. These two\nsituations can only be distinguished by determining the enzyme activity (phenotyping).\nLiterature:\n1\n. \nCubero DI et al. Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine\ndehydrogenase deficiency: a proof of principle. Ther Adv Med Oncol 2012;4:167-72.\n2\n. \nDeenen MJ et al. Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or\ncapecitabine. Ann Intern Med 2010;153:767-8.\n3\n. \nSPC Teysuno.\nDate 20-11-2017\nDPD genact 0: tegafur\n2553\nGenetic variation increases the risk of severe, possibly fatal toxicity. A reduced conversion of tegafur to inactive metabolites means that", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2628, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5012c871-a6d4-47f6-bd6c-74f4824a2b18": {"__data__": {"id_": "5012c871-a6d4-47f6-bd6c-74f4824a2b18", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 3, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 3, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "ac3e6c8d56c934b044824372f7b0dc62cc62cbd4a9f84952c311dd72536596b7", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "9c3f8a89-7eab-42f2-ad46-7eac6a5e8a5a", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 3, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "6db23416641e461bc4dfa4a04be117660458867c4a2d2f3bae3c66dd32e74bd6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Cancer Res 2005;7:R284-90.\n32\n. \nSPC Tamoxifen PCH.\nDate 09-11-2015\nCYP2D6 UM: tamoxifen\n1603\nNO action is needed for this gene-drug interaction.\nAs a result of the genetic variation, the plasma concentration of the active metabolites 4-hydroxytamoxifen and endoxifen can increase.\nHowever, there is no evidence that this results in an increase in the side effects.\nLiterature:\n1\n. \nMartinez de Due\u00f1as E et al. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer\nphenotype. Breast 2014;23:400-6.\n2\n. \nSchroth W et al. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded\npolymorphism coverage improves risk stratification. Clin Cancer Res 2010;16:4468-77.\n3\n. \nGjerde J et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.\nAnn Oncol 2008;19:56-61.\n4\n. \nLim HS et al. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J\nClin Oncol 2007;25:3837-45.\nDate 09-11-2015\nDPD genact 0,5: tegafur\n4891\nGenetic variation increases the risk of severe, possibly fatal toxicity. A reduced conversion of tegafur to inactive metabolites means that\nthe normal dose is an overdose.\nRecommendation:\nChoose an alternative or start with a low dose and adjust the initial dose based on toxicity and efficacy\nFluorouracil and capecitabine are not alternatives, as these are also metabolised by DPD.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1488, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "193ca1aa-5fdf-4adb-9fcc-f8ebe5e2ef23": {"__data__": {"id_": "193ca1aa-5fdf-4adb-9fcc-f8ebe5e2ef23", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 3, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 3, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "ac3e6c8d56c934b044824372f7b0dc62cc62cbd4a9f84952c311dd72536596b7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5012c871-a6d4-47f6-bd6c-74f4824a2b18", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 3, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "a46f935119d4d1ddf9d004b3f07cecb72b060dd167f4552bf1e7f2c3fcfcabd3", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "9c3f8a89-7eab-42f2-ad46-7eac6a5e8a5a", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 3, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}, "hash": "6db23416641e461bc4dfa4a04be117660458867c4a2d2f3bae3c66dd32e74bd6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "It is not possible to offer substantiated advice for dose reduction based on the literature. For fluorouracil and capecitabine, starting\nwith 25% of the standard dose is recommended.\nNOTE: This recommendation only applies if the two gene variations are on a different allele. If both variations are on the same\nallele, this patient has gene activity score 1 and the recommendation for that gene activity score should be followed. These two\nsituations can only be distinguished by determining the enzyme activity (phenotyping).\nLiterature:\n1\n. \nCubero DI et al. Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine\ndehydrogenase deficiency: a proof of principle. Ther Adv Med Oncol 2012;4:167-72.\n2\n. \nDeenen MJ et al. Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or\ncapecitabine. Ann Intern Med 2010;153:767-8.\n3\n. \nSPC Teysuno.\nDate 20-11-2017\nDPD genact 0: tegafur\n2553\nGenetic variation increases the risk of severe, possibly fatal toxicity. A reduced conversion of tegafur to inactive metabolites means that", "mimetype": "text/plain", "start_char_idx": 1489, "end_char_idx": 2628, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9b598374-0d56-439a-8d8e-8cfddf1a1b92": {"__data__": {"id_": "9b598374-0d56-439a-8d8e-8cfddf1a1b92", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "20", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "8cafb37166b38c12c2d8fe7356f3b6d84d6bc55d9265f02d0f5f0d8f5d550138", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "94c6984c-a49e-44ab-bdb4-1c06a14fcaa0", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "90e4ae755b6e6b918dd53ec42f9fa811c672ad96e2be71a73400f1c46defeb91", "class_name": "RelatedNodeInfo"}, {"node_id": "71e1577f-3c36-424f-8bc2-b71cbba28ae3", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "7b81803d283427a490eef4d3dfaf76f4d09f5671be549bf9bc7d8f2df52fdbc2", "class_name": "RelatedNodeInfo"}, {"node_id": "3273f083-db3d-4b38-8667-79c1a5da6848", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "e5168ff4283e47f0b1e724bce524c482cf48da14be19ea29b26d08a893b851ed", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Literature:\n1\n. \nSPC Anatensol decanoaat.\nDate 26-05-2009\nDPD genact 0: fluorouracil cutaan\n6192\nGenetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive\nmetabolites means that the normal dose is an overdose.\nRecommendation:\nChoose an alternative\nNOTE: If a patient has two different genetic variations that lead to a non-functional DPD enzyme (e.g. *2A and* 13), this\nrecommendation only applies if the variations are on a different allele.\nIf both variations are on the same allele, this patient has gene activity score 1, for which no increased risk of severe, potentially\nfatal toxicity has been found with cutaneous use. These two situations can only be distinguished by determining the enzyme\nactivity (phenotyping).\nLiterature:\n1\n. \nHenricks LM et al. Treatment algorithm for homozygous or compound heterozygous DPYD variant allele carriers with low-dose\ncapecitabine. JCO Precis Oncol 2017 Oct 8 [Epub ahead of print].\n2\n. \nHenricks LM et al. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine\ndehydrogenase deficiency. Int J Cancer 2017 Sep 20 [Epub ahead of print].\n3\n. \nKodali S et al. Capecitabine-induced severe toxicity secondary to DPD deficiency and successful treatment with low dose 5-\nfluorouracil. J Gastrointest Cancer 2017;48:66-69.\n4\n. \nLunenburg CA et al. Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-\ntreated patients. Pharmacogenomics 2016;17:721-9.\n5\n. \nDeenen MJ et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin\nOncol 2016;34:227-34.\n6\n. \nRosmarin D et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the\nQUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 2014; 32:1031-9.\n7\n. \nDeenen MJ et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of\ncapecitabine in advanced colorectal cancer. Clin Cancer Res 2011; 17:3455-68.\n8\n. \nGross E et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-\nrelated toxicity in cancer patients. PLoS ONE 2008;3:e4003.\n9\n. \nBoisdron-Celle M et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection\nof dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2007;249:271-82.\n10\n. \nMorel A et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-\nfluorouracil tolerance. Mol Cancer Ther 2006;5:2895-904.\n11\n. \nVan Kuilenburg AB et al. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of\npatients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002;12:555-8.\n12\n. \nRaida M et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice\ndonor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res\n2001;7:2832-9.\n13\n. \nvan Kuilenburg AB et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-\nfluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000;6:4705-12.\n14\n. \nJohnson MR et al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-\nfluorouracil. Clin Cancer Res 1999;5:2006-11.\n15\n. \nSPC Efudix cr\u00e8me en Carac cream (VS).\nDate 20-11-2017\nDPD genact 0,5: fluorouracil/capecitabine\n4893\nGenetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive\nmetabolites means that the normal dose is an overdose.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3928, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "94c6984c-a49e-44ab-bdb4-1c06a14fcaa0": {"__data__": {"id_": "94c6984c-a49e-44ab-bdb4-1c06a14fcaa0", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "20", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "8cafb37166b38c12c2d8fe7356f3b6d84d6bc55d9265f02d0f5f0d8f5d550138", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "9b598374-0d56-439a-8d8e-8cfddf1a1b92", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "ab234f8961688f14461d534dd1e1753598b429bfc0b241ac7972d2c2547c4d79", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Literature:\n1\n. \nSPC Anatensol decanoaat.\nDate 26-05-2009\nDPD genact 0: fluorouracil cutaan\n6192\nGenetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive\nmetabolites means that the normal dose is an overdose.\nRecommendation:\nChoose an alternative\nNOTE: If a patient has two different genetic variations that lead to a non-functional DPD enzyme (e.g. *2A and* 13), this\nrecommendation only applies if the variations are on a different allele.\nIf both variations are on the same allele, this patient has gene activity score 1, for which no increased risk of severe, potentially\nfatal toxicity has been found with cutaneous use. These two situations can only be distinguished by determining the enzyme\nactivity (phenotyping).\nLiterature:\n1\n. \nHenricks LM et al. Treatment algorithm for homozygous or compound heterozygous DPYD variant allele carriers with low-dose\ncapecitabine. JCO Precis Oncol 2017 Oct 8 [Epub ahead of print].\n2\n. \nHenricks LM et al. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine\ndehydrogenase deficiency. Int J Cancer 2017 Sep 20 [Epub ahead of print].\n3\n. \nKodali S et al. Capecitabine-induced severe toxicity secondary to DPD deficiency and successful treatment with low dose 5-\nfluorouracil. J Gastrointest Cancer 2017;48:66-69.\n4\n. \nLunenburg CA et al. Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-\ntreated patients.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1532, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "71e1577f-3c36-424f-8bc2-b71cbba28ae3": {"__data__": {"id_": "71e1577f-3c36-424f-8bc2-b71cbba28ae3", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "20", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "8cafb37166b38c12c2d8fe7356f3b6d84d6bc55d9265f02d0f5f0d8f5d550138", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94c6984c-a49e-44ab-bdb4-1c06a14fcaa0", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "90e4ae755b6e6b918dd53ec42f9fa811c672ad96e2be71a73400f1c46defeb91", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "9b598374-0d56-439a-8d8e-8cfddf1a1b92", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "ab234f8961688f14461d534dd1e1753598b429bfc0b241ac7972d2c2547c4d79", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Pharmacogenomics 2016;17:721-9.\n5\n. \nDeenen MJ et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin\nOncol 2016;34:227-34.\n6\n. \nRosmarin D et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the\nQUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 2014; 32:1031-9.\n7\n. \nDeenen MJ et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of\ncapecitabine in advanced colorectal cancer. Clin Cancer Res 2011; 17:3455-68.\n8\n. \nGross E et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-\nrelated toxicity in cancer patients. PLoS ONE 2008;3:e4003.\n9\n. \nBoisdron-Celle M et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection\nof dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2007;249:271-82.\n10\n. \nMorel A et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-\nfluorouracil tolerance. Mol Cancer Ther 2006;5:2895-904.\n11\n. \nVan Kuilenburg AB et al.", "mimetype": "text/plain", "start_char_idx": 1533, "end_char_idx": 2745, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3273f083-db3d-4b38-8667-79c1a5da6848": {"__data__": {"id_": "3273f083-db3d-4b38-8667-79c1a5da6848", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "20", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "8cafb37166b38c12c2d8fe7356f3b6d84d6bc55d9265f02d0f5f0d8f5d550138", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71e1577f-3c36-424f-8bc2-b71cbba28ae3", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "7b81803d283427a490eef4d3dfaf76f4d09f5671be549bf9bc7d8f2df52fdbc2", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "9b598374-0d56-439a-8d8e-8cfddf1a1b92", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "ab234f8961688f14461d534dd1e1753598b429bfc0b241ac7972d2c2547c4d79", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "11\n. \nVan Kuilenburg AB et al. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of\npatients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002;12:555-8.\n12\n. \nRaida M et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice\ndonor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res\n2001;7:2832-9.\n13\n. \nvan Kuilenburg AB et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-\nfluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000;6:4705-12.\n14\n. \nJohnson MR et al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-\nfluorouracil. Clin Cancer Res 1999;5:2006-11.\n15\n. \nSPC Efudix cr\u00e8me en Carac cream (VS).\nDate 20-11-2017\nDPD genact 0,5: fluorouracil/capecitabine\n4893\nGenetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive\nmetabolites means that the normal dose is an overdose.", "mimetype": "text/plain", "start_char_idx": 2715, "end_char_idx": 3928, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "36f34188-c210-4cde-8d5e-4ce823868833": {"__data__": {"id_": "36f34188-c210-4cde-8d5e-4ce823868833", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "21", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "71c501ca5d250c22cf126f7ed0a75fde18db913c38ac6d6c908dde935cb64f7b", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "b44735f9-dcfe-49f4-b843-646890feff8f", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "6396c4748966077e51508c0a118bebab995c99eb8e2b3c9986342cc9200a315b", "class_name": "RelatedNodeInfo"}, {"node_id": "a0f5dc73-3e75-4134-83e7-a0060ff196cc", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "4d6f425df7e2c0ce25f0e9355fc3239ee70b035743d3e551444d5bf3d578b1a8", "class_name": "RelatedNodeInfo"}, {"node_id": "8c845ae6-8415-4719-8aa3-51143c294121", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "eada74b526ac178429c528883e34948af0eb9651d2f6e49d604ec0a0003b8573", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Recommendation:\n\u200b\nStart with 25% of the standard dose or choose an alternative.\nAdjustment of the initial dose should be guided by toxicity and effectiveness.\nTegafur is not an alternative, as this is also metabolised by DPD.\nNOTE: This recommendation only applies if the two genetic variations are on a different allele.\nIf both variations are on the same allele, this patient has gene activity score 1 and the recommendation for that gene activity score\nshould be followed. These two situations can only be distinguished by determining the enzyme activity (phenotyping).\nLiterature:\n1\n. \nKodali S et al. Capecitabine-induced severe toxicity secondary to DPD deficiency and successful treatment with low dose 5-\nfluorouracil. J Gastrointest Cancer 2017;48:66-69.\n2\n. \nLunenburg CA et al. Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-\ntreated patients. Pharmacogenomics 2016;17:721-9.\n3\n. \nDeenen MJ et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin\nOncol 2016;34:227-34.\n4\n. \nLee AM et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl\nCancer Inst 2014;106:dju298.\n5\n. \nDeenen MJ et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of\ncapecitabine in advanced colorectal cancer. Clin Cancer Res 2011; 17:3455-68.\n6\n. \nBoisdron-Celle M et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection\nof dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2007;249:271-82.\n7\n. \nMorel A et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-\nfluorouracil tolerance. Mol Cancer Ther 2006;5:2895-904.\n8\n. \nSPC\u2019s Fluorouracil PCH, Xeloda, Efudix cr\u00e8me, Fluorouracil (VS), en Xeloda (VS).\nDate 20-11-2017\nDPD genact 1,5: fluorouracil/capecitabine\n4894\nGenetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive\nmetabolites means that the normal dose is an overdose.\nRecommendation:\nStart with 75% of the standard dose or choose an alternative.\nAdjustment of the initial dose should be guided by toxicity and effectiveness.\nTegafur is not an alternative, as this is also metabolised by DPD.\nLiterature:\n1\n. \nMeulendijks D et al. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated\ntoxicity. Br J Cancer 2017;116:1415-24.\n2\n. \nLunenburg CA et al. Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-\ntreated patients. Pharmacogenomics 2016;17:721-9.\n3\n. \nLee AM et al. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in\nstage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics 2016;26:133-7.\n4\n. \nMeulendijks D et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe\nfluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol\n2015;16:1639-50.\n5\n. \nLee AM et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl\nCancer Inst 2014;106:dju298.\n6\n. \nRosmarin D et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the\nQUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 2014; 32:1031-9.\n7\n. \nTerrazzino S et al. DPYD IVS14+1 G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity:\na meta-analysis. Pharmacogenomics2013; 14:1255-72.\n8\n. \nDeenen MJ et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of\ncapecitabine in advanced colorectal cancer. Clin Cancer Res 2011; 17:3455-68.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 4023, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "b44735f9-dcfe-49f4-b843-646890feff8f": {"__data__": {"id_": "b44735f9-dcfe-49f4-b843-646890feff8f", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "21", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "71c501ca5d250c22cf126f7ed0a75fde18db913c38ac6d6c908dde935cb64f7b", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "36f34188-c210-4cde-8d5e-4ce823868833", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "c94e23a701effcb327d74e394f3699e8651b7246f20b51434e79ba5d5aa7e9d6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Recommendation:\n\u200b\nStart with 25% of the standard dose or choose an alternative.\nAdjustment of the initial dose should be guided by toxicity and effectiveness.\nTegafur is not an alternative, as this is also metabolised by DPD.\nNOTE: This recommendation only applies if the two genetic variations are on a different allele.\nIf both variations are on the same allele, this patient has gene activity score 1 and the recommendation for that gene activity score\nshould be followed. These two situations can only be distinguished by determining the enzyme activity (phenotyping).\nLiterature:\n1\n. \nKodali S et al. Capecitabine-induced severe toxicity secondary to DPD deficiency and successful treatment with low dose 5-\nfluorouracil. J Gastrointest Cancer 2017;48:66-69.\n2\n. \nLunenburg CA et al. Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-\ntreated patients. Pharmacogenomics 2016;17:721-9.\n3\n. \nDeenen MJ et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin\nOncol 2016;34:227-34.\n4\n. \nLee AM et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl\nCancer Inst 2014;106:dju298.\n5\n. \nDeenen MJ et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of\ncapecitabine in advanced colorectal cancer. Clin Cancer Res 2011; 17:3455-68.\n6\n. \nBoisdron-Celle M et al.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1489, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "a0f5dc73-3e75-4134-83e7-a0060ff196cc": {"__data__": {"id_": "a0f5dc73-3e75-4134-83e7-a0060ff196cc", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "21", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "71c501ca5d250c22cf126f7ed0a75fde18db913c38ac6d6c908dde935cb64f7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b44735f9-dcfe-49f4-b843-646890feff8f", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "6396c4748966077e51508c0a118bebab995c99eb8e2b3c9986342cc9200a315b", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "36f34188-c210-4cde-8d5e-4ce823868833", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "c94e23a701effcb327d74e394f3699e8651b7246f20b51434e79ba5d5aa7e9d6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "6\n. \nBoisdron-Celle M et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection\nof dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2007;249:271-82.\n7\n. \nMorel A et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-\nfluorouracil tolerance. Mol Cancer Ther 2006;5:2895-904.\n8\n. \nSPC\u2019s Fluorouracil PCH, Xeloda, Efudix cr\u00e8me, Fluorouracil (VS), en Xeloda (VS).\nDate 20-11-2017\nDPD genact 1,5: fluorouracil/capecitabine\n4894\nGenetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive\nmetabolites means that the normal dose is an overdose.\nRecommendation:\nStart with 75% of the standard dose or choose an alternative.\nAdjustment of the initial dose should be guided by toxicity and effectiveness.\nTegafur is not an alternative, as this is also metabolised by DPD.\nLiterature:\n1\n. \nMeulendijks D et al. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated\ntoxicity. Br J Cancer 2017;116:1415-24.\n2\n. \nLunenburg CA et al. Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-\ntreated patients. Pharmacogenomics 2016;17:721-9.\n3\n. \nLee AM et al.", "mimetype": "text/plain", "start_char_idx": 1461, "end_char_idx": 2802, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "8c845ae6-8415-4719-8aa3-51143c294121": {"__data__": {"id_": "8c845ae6-8415-4719-8aa3-51143c294121", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "21", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "71c501ca5d250c22cf126f7ed0a75fde18db913c38ac6d6c908dde935cb64f7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0f5dc73-3e75-4134-83e7-a0060ff196cc", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "4d6f425df7e2c0ce25f0e9355fc3239ee70b035743d3e551444d5bf3d578b1a8", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "36f34188-c210-4cde-8d5e-4ce823868833", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "c94e23a701effcb327d74e394f3699e8651b7246f20b51434e79ba5d5aa7e9d6", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "3\n. \nLee AM et al. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in\nstage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics 2016;26:133-7.\n4\n. \nMeulendijks D et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe\nfluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol\n2015;16:1639-50.\n5\n. \nLee AM et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl\nCancer Inst 2014;106:dju298.\n6\n. \nRosmarin D et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the\nQUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 2014; 32:1031-9.\n7\n. \nTerrazzino S et al. DPYD IVS14+1 G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity:\na meta-analysis. Pharmacogenomics2013; 14:1255-72.\n8\n. \nDeenen MJ et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of\ncapecitabine in advanced colorectal cancer. Clin Cancer Res 2011; 17:3455-68.", "mimetype": "text/plain", "start_char_idx": 2784, "end_char_idx": 4023, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "c5e631f8-577b-4b4b-8b0f-01af4d02907b": {"__data__": {"id_": "c5e631f8-577b-4b4b-8b0f-01af4d02907b", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "22", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "50992d8acbdb286d344b785a4d40ad551991b591c104e552821623359b8d2e24", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "5a90d14b-2f82-4d64-b597-17d8d3e9dc64", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "d0717563f0fca678bb9ca1e803cce0df0f7258f2aac532d8784e6ee55038ff6c", "class_name": "RelatedNodeInfo"}, {"node_id": "bbf28d45-4656-480a-86cb-7cd1882ceb16", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "5fd0956cefd1be5e703238175695d4dd31e861943b305164de122afc74827cf8", "class_name": "RelatedNodeInfo"}, {"node_id": "2625ae14-d3f1-44b2-b3a8-62950da83fb4", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "3bf52428f79f9bbaf54e2402e2d252fe26d4389cae495ab70c6bc84f6b807ade", "class_name": "RelatedNodeInfo"}, {"node_id": "baf2b098-1a60-492d-a258-05248db633b6", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "cd0f13930c937805200f9ae318dc527b6e94e5bf4960be3f20634293b76ecb85", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "9\n. \nKristensen MH et al. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate\nsynthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients. J Int Med Res 2010; 38:870-83.\n10\n. \nGross E et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-\nrelated toxicity in cancer patients. PLoS ONE 2008;3:e4003.\n11\n. \nCapitain O et al. The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal\ncancer. Pharmacogenomics J 2008;8:256-67.\n12\n. \nBoisdron-Celle M et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection\nof dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2007;249:271-82.\n13\n. \nCho HJ et al. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean\npopulation for prediction of 5-fluorouracil-associated toxicity. Ther Drug Monit 2007;29:190-6.\n14\n. \nMorel A et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-\nfluorouracil tolerance. Mol Cancer Ther 2006;5:2895-904.\n15\n. \nYamaguchi K et al. Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to\ntoxicity to 5-fluorouracil. Jpn J Cancer Res 2001;92:337-42.\n16\n. \nvan Kuilenburg AB et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-\nfluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000;6:4705-12.\n17\n. \nSPC\u2019s Fluorouracil PCH, Xeloda, Efudix cr\u00e8me, Fluorouracil (VS) en Xeloda (VS).\nDate 20-11-2017\nDPD genact 1: fluorouracil/capecitabine\n2552\nGenetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive\nmetabolites means that the normal dose is an overdose.\nRecommendation:\nStart with 50% of the standard dose or choose an alternative.\nAdjustment of the initial dose should be guided by toxicity and effectiveness.\nTegafur is not an alternative, as this is also metabolised by DPD.\nNB1: The dose reduction described here is well substantiated for *1/*2A and 1236A/1236A.\nThe dose reduction for patients with 2846T (2846T/2846T or 1236A/2846T) is based on, among other factors, the dose reductions\nidentified for *1/2846T.\nNB2: If a patient has two different genetic variations that result in a partially functional DPD enzyme (e.g. 2846T and 1236A), this\nrecommendation applies if the variations are on a different allele. If both variations are on the same allele, the gene activity score\nis between 1 and 1.5, depending on whether and how the two gene variations influence each other and on other factors that\ninfluence the DPD activity. Whether a gene activity score of 1 or 1.5 needs to be assigned in the case of two different genetic\nvariations can only be determined by measuring the enzyme activity (phenotyping).\nLiterature:\n1\n. \nHenricks LM et al. Treatment algorithm for homozygous or compound heterozygous DPYD variant allele carriers with low-dose\ncapecitabine. JCO Precis Oncol 2017 Oct 8 [Epub ahead of print].\n2\n. \nMeulendijks D et al. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated\ntoxicity. Br J Cancer 2017;116:1415-24.\n3\n. \nKodali S et al. Capecitabine-induced severe toxicity secondary to DPD deficiency and successful treatment with low dose 5-\nfluorouracil. J Gastrointest Cancer 2017;48:66-69.\n4\n. \nMeulendijks D et al. Patients homozygous for DPYD c.1129-5923C>G/ haplotype B3 have partial DPD deficiency and require a\ndose reduction when treated with fluoropyrimidines. Cancer Chemother Pharmacol 2016;78:875-80.\n5\n. \nLunenburg CA et al. Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-\ntreated patients. Pharmacogenomics 2016;17:721-9.\n6\n. \nLee AM et al. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in\nstage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics 2016;26:133-7.\n7\n. \nDeenen MJ et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin\nOncol 2016;34:227-34.\n8\n. \nMeulendijks D et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe\nfluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol\n2015;16:1639-50.\n9\n. \nLee AM et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl\nCancer Inst 2014;106:dju298.\n10\n. \nRosmarin D et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the\nQUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 2014; 32:1031-9.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 5019, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "5a90d14b-2f82-4d64-b597-17d8d3e9dc64": {"__data__": {"id_": "5a90d14b-2f82-4d64-b597-17d8d3e9dc64", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "22", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "50992d8acbdb286d344b785a4d40ad551991b591c104e552821623359b8d2e24", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "c5e631f8-577b-4b4b-8b0f-01af4d02907b", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "5685c7890375b5ef795b3a90607740b7011cda4e111b5cda4af935ad95887034", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "9\n. \nKristensen MH et al. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate\nsynthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients. J Int Med Res 2010; 38:870-83.\n10\n. \nGross E et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-\nrelated toxicity in cancer patients. PLoS ONE 2008;3:e4003.\n11\n. \nCapitain O et al. The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal\ncancer. Pharmacogenomics J 2008;8:256-67.\n12\n. \nBoisdron-Celle M et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection\nof dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2007;249:271-82.\n13\n. \nCho HJ et al. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean\npopulation for prediction of 5-fluorouracil-associated toxicity. Ther Drug Monit 2007;29:190-6.\n14\n. \nMorel A et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-\nfluorouracil tolerance. Mol Cancer Ther 2006;5:2895-904.\n15\n. \nYamaguchi K et al.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1245, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "bbf28d45-4656-480a-86cb-7cd1882ceb16": {"__data__": {"id_": "bbf28d45-4656-480a-86cb-7cd1882ceb16", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "22", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "50992d8acbdb286d344b785a4d40ad551991b591c104e552821623359b8d2e24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a90d14b-2f82-4d64-b597-17d8d3e9dc64", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "d0717563f0fca678bb9ca1e803cce0df0f7258f2aac532d8784e6ee55038ff6c", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "c5e631f8-577b-4b4b-8b0f-01af4d02907b", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "5685c7890375b5ef795b3a90607740b7011cda4e111b5cda4af935ad95887034", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "15\n. \nYamaguchi K et al. Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to\ntoxicity to 5-fluorouracil. Jpn J Cancer Res 2001;92:337-42.\n16\n. \nvan Kuilenburg AB et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-\nfluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000;6:4705-12.\n17\n. \nSPC\u2019s Fluorouracil PCH, Xeloda, Efudix cr\u00e8me, Fluorouracil (VS) en Xeloda (VS).\nDate 20-11-2017\nDPD genact 1: fluorouracil/capecitabine\n2552\nGenetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive\nmetabolites means that the normal dose is an overdose.\nRecommendation:\nStart with 50% of the standard dose or choose an alternative.\nAdjustment of the initial dose should be guided by toxicity and effectiveness.\nTegafur is not an alternative, as this is also metabolised by DPD.\nNB1: The dose reduction described here is well substantiated for *1/*2A and 1236A/1236A.\nThe dose reduction for patients with 2846T (2846T/2846T or 1236A/2846T) is based on, among other factors, the dose reductions\nidentified for *1/2846T.\nNB2: If a patient has two different genetic variations that result in a partially functional DPD enzyme (e.g. 2846T and 1236A), this\nrecommendation applies if the variations are on a different allele.", "mimetype": "text/plain", "start_char_idx": 1221, "end_char_idx": 2659, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "2625ae14-d3f1-44b2-b3a8-62950da83fb4": {"__data__": {"id_": "2625ae14-d3f1-44b2-b3a8-62950da83fb4", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "22", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "50992d8acbdb286d344b785a4d40ad551991b591c104e552821623359b8d2e24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbf28d45-4656-480a-86cb-7cd1882ceb16", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "5fd0956cefd1be5e703238175695d4dd31e861943b305164de122afc74827cf8", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "c5e631f8-577b-4b4b-8b0f-01af4d02907b", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "5685c7890375b5ef795b3a90607740b7011cda4e111b5cda4af935ad95887034", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "If both variations are on the same allele, the gene activity score\nis between 1 and 1.5, depending on whether and how the two gene variations influence each other and on other factors that\ninfluence the DPD activity. Whether a gene activity score of 1 or 1.5 needs to be assigned in the case of two different genetic\nvariations can only be determined by measuring the enzyme activity (phenotyping).\nLiterature:\n1\n. \nHenricks LM et al. Treatment algorithm for homozygous or compound heterozygous DPYD variant allele carriers with low-dose\ncapecitabine. JCO Precis Oncol 2017 Oct 8 [Epub ahead of print].\n2\n. \nMeulendijks D et al. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated\ntoxicity. Br J Cancer 2017;116:1415-24.\n3\n. \nKodali S et al. Capecitabine-induced severe toxicity secondary to DPD deficiency and successful treatment with low dose 5-\nfluorouracil. J Gastrointest Cancer 2017;48:66-69.\n4\n. \nMeulendijks D et al. Patients homozygous for DPYD c.1129-5923C>G/ haplotype B3 have partial DPD deficiency and require a\ndose reduction when treated with fluoropyrimidines. Cancer Chemother Pharmacol 2016;78:875-80.\n5\n. \nLunenburg CA et al. Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-\ntreated patients. Pharmacogenomics 2016;17:721-9.\n6\n. \nLee AM et al.", "mimetype": "text/plain", "start_char_idx": 2660, "end_char_idx": 4030, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "baf2b098-1a60-492d-a258-05248db633b6": {"__data__": {"id_": "baf2b098-1a60-492d-a258-05248db633b6", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "22", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "50992d8acbdb286d344b785a4d40ad551991b591c104e552821623359b8d2e24", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2625ae14-d3f1-44b2-b3a8-62950da83fb4", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "3bf52428f79f9bbaf54e2402e2d252fe26d4389cae495ab70c6bc84f6b807ade", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "c5e631f8-577b-4b4b-8b0f-01af4d02907b", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "5685c7890375b5ef795b3a90607740b7011cda4e111b5cda4af935ad95887034", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "6\n. \nLee AM et al. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in\nstage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics 2016;26:133-7.\n7\n. \nDeenen MJ et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin\nOncol 2016;34:227-34.\n8\n. \nMeulendijks D et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe\nfluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol\n2015;16:1639-50.\n9\n. \nLee AM et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl\nCancer Inst 2014;106:dju298.\n10\n. \nRosmarin D et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the\nQUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 2014; 32:1031-9.", "mimetype": "text/plain", "start_char_idx": 4012, "end_char_idx": 5019, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "92a5e5c2-5060-4070-b454-27d62534987e": {"__data__": {"id_": "92a5e5c2-5060-4070-b454-27d62534987e", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "23", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "130e7555a70abe4469e920e090af47bb25aea809541373f8ef9d991c843445dc", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "916f94a0-3349-48e9-8d9f-5af02adb6617", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "1489d86af0ba266a38bf3e0136da9172998019bfa73f82572c6ca0992af837d4", "class_name": "RelatedNodeInfo"}, {"node_id": "cfe5cf7e-aa1c-4371-8bad-53c31945979c", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "7ceddd79527cde2c72ecb80eb26064b55f645a7f735168b10886e8cf0e5d0905", "class_name": "RelatedNodeInfo"}, {"node_id": "08df4c06-fea7-4612-95d0-c0697ce27a8a", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "2fbfe5a836c8136f89252b8431087df86b63e24d9e7308856d45554b014cf146", "class_name": "RelatedNodeInfo"}, {"node_id": "92073f68-c3af-4d5b-89c6-ee8a628c1fdd", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "32ba788b58c256b81671bec0f503d1d74a92cd9e2ac85faed19102cbb98e8f6b", "class_name": "RelatedNodeInfo"}, {"node_id": "9840e038-dfe5-42ce-ae73-339df30d7da7", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "2777dc9b159b85f7a02f2c910c4a2aa3d00340b7d01a812af1eeb1215bb84e7e", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "11\n. \nTerrazzino S et al. DPYD IVS14+1 G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity:\na meta-analysis. Pharmacogenomics2013; 14:1255-72.\n12\n. \nMagnani E et al. Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for\nfurther revision of dose and schedule. Intern Emerg Med 2013; 8:417-23.\n13\n. \nVulsteke C et al. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological\ntoxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide\n(FEC). Ann Oncol 2013; 24:1513-25.\n14\n. \nvan Kuilenburg AB et al. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1 G>A mutation in\nDPYD by means of a Bayesian limited sampling strategy. Clin Pharmacokinet 2012;51:163-74.\n15\n. \nDeenen MJ et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of\ncapecitabine in advanced colorectal cancer. Clin Cancer Res 2011; 17:3455-68.\n16\n. \nGross E et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-\nrelated toxicity in cancer patients. PLoS ONE 2008;3:e4003.\n17\n. \nCapitain O et al. The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal\ncancer. Pharmacogenomics J 2008;8:256-67.\n18\n. \nSulzyc-Bielicka V et al. 5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase\ngene in Polish colorectal cancer patients. Pharmacol Rep 2008;60:238-42.\n19\n. \nSchwab M et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical\ntrial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008;26:2131-8.\n20\n. \nMercier C et al. Prospective phenotypic screening for DPD deficiency prior to 5-FU administration: Decrease in toxicity, not in\nefficacy. J Clin Oncol 2008;26(May 20 suppl):abstr 14556. (meeting abstract)\n21\n. \nJatoi A et al. Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of\npreliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment\nGroup (N0044). Am J Clin Oncol 2007;30:507-13.\n22\n. \nMagn\u00e9 N et al. Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related\ntoxicity. Br J Clin Pharmacol 2007;64:237-40.\n23\n. \nSaif MW et al. Dihydropyrimidine dehydrogenase deficiency (GPD) in GI malignancies: experience of 4-years. Pak J Med Sci Q\n2007;23:832-9.\n24\n. \nBoisdron-Celle M et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection\nof dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2007;249:271-82.\n25\n. \nCho HJ et al. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean\npopulation for prediction of 5-fluorouracil-associated toxicity. Ther Drug Monit 2007;29:190-6.\n26\n. \nSalgado J et al. Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and\ntoxicity to capecitabine-raltitrexed in colorectal cancer. Oncol Rep 2007;17:325-8.\n27\n. \nMorel A et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-\nfluorouracil tolerance. Mol Cancer Ther 2006;5:2895-904.\n28\n. \nLargillier R et al. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer Res 2006;12:5496-502.\n29\n. \nSalgueiro N et al. Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal\ncancer patients. Genet Med 2004;6:102-7.\n30\n. \nVan Kuilenburg AB et al. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of\npatients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002;12:555-8.\n31\n. \nRaida M et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice\ndonor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res\n2001;7:2832-9.\n32\n. \nvan Kuilenburg AB et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-\nfluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000;6:4705-12.\n33\n. \nSPC\u2019s Fluorouracil PCH, Xeloda, Efudix cr\u00e8me, Fluorouracil (VS) en Xeloda (VS).\nDate 20-11-2017\nDPD genact 0: fluorouracil/capecitabine,systemisch\n2551\nGenetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive\nmetabolites means that the standard dose is a more than 100-fold overdose.\nRecommendation:\n1\n. \nChoose an alternative\nTegafur is not an alternative, as this is also metabolised by DPD.\n2\n. \nIf an alternative is not possible:\ndetermine the residual DPD activity in mononuclear cells from peripheral blood and adjust the initial dose accordingly.\nA patient with 0.5% of the normal DPD activity tolerated 0.8% of the standard dose (150 mg capecitabine every 5 days). A\npatient with undetectable DPD activity tolerated 0.43% of the standard dose (150 mg capecitabine every 5 days with every\nthird dose skipped)\nThe average Caucasian DPD activity is 9.9 nmol/hour per mg protein.\nadjust the initial dose based on toxicity and efficacy.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 5596, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "916f94a0-3349-48e9-8d9f-5af02adb6617": {"__data__": {"id_": "916f94a0-3349-48e9-8d9f-5af02adb6617", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "23", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "130e7555a70abe4469e920e090af47bb25aea809541373f8ef9d991c843445dc", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "92a5e5c2-5060-4070-b454-27d62534987e", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "c120bf11efe73f3d878e31bb8ecf2a08e0806e9fa6fb93db79a31d2d20889530", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "11\n. \nTerrazzino S et al. DPYD IVS14+1 G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity:\na meta-analysis. Pharmacogenomics2013; 14:1255-72.\n12\n. \nMagnani E et al. Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for\nfurther revision of dose and schedule. Intern Emerg Med 2013; 8:417-23.\n13\n. \nVulsteke C et al. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological\ntoxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide\n(FEC). Ann Oncol 2013; 24:1513-25.\n14\n. \nvan Kuilenburg AB et al. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1 G>A mutation in\nDPYD by means of a Bayesian limited sampling strategy. Clin Pharmacokinet 2012;51:163-74.\n15\n. \nDeenen MJ et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of\ncapecitabine in advanced colorectal cancer. Clin Cancer Res 2011; 17:3455-68.\n16\n. \nGross E et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-\nrelated toxicity in cancer patients. PLoS ONE 2008;3:e4003.\n17\n. \nCapitain O et al.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1307, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "cfe5cf7e-aa1c-4371-8bad-53c31945979c": {"__data__": {"id_": "cfe5cf7e-aa1c-4371-8bad-53c31945979c", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "23", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "130e7555a70abe4469e920e090af47bb25aea809541373f8ef9d991c843445dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "916f94a0-3349-48e9-8d9f-5af02adb6617", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "1489d86af0ba266a38bf3e0136da9172998019bfa73f82572c6ca0992af837d4", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "92a5e5c2-5060-4070-b454-27d62534987e", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "c120bf11efe73f3d878e31bb8ecf2a08e0806e9fa6fb93db79a31d2d20889530", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "17\n. \nCapitain O et al. The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal\ncancer. Pharmacogenomics J 2008;8:256-67.\n18\n. \nSulzyc-Bielicka V et al. 5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase\ngene in Polish colorectal cancer patients. Pharmacol Rep 2008;60:238-42.\n19\n. \nSchwab M et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical\ntrial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008;26:2131-8.\n20\n. \nMercier C et al. Prospective phenotypic screening for DPD deficiency prior to 5-FU administration: Decrease in toxicity, not in\nefficacy. J Clin Oncol 2008;26(May 20 suppl):abstr 14556. (meeting abstract)\n21\n. \nJatoi A et al. Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of\npreliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment\nGroup (N0044). Am J Clin Oncol 2007;30:507-13.\n22\n. \nMagn\u00e9 N et al. Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related\ntoxicity. Br J Clin Pharmacol 2007;64:237-40.\n23\n. \nSaif MW et al.", "mimetype": "text/plain", "start_char_idx": 1284, "end_char_idx": 2585, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "08df4c06-fea7-4612-95d0-c0697ce27a8a": {"__data__": {"id_": "08df4c06-fea7-4612-95d0-c0697ce27a8a", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "23", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "130e7555a70abe4469e920e090af47bb25aea809541373f8ef9d991c843445dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfe5cf7e-aa1c-4371-8bad-53c31945979c", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "7ceddd79527cde2c72ecb80eb26064b55f645a7f735168b10886e8cf0e5d0905", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "92a5e5c2-5060-4070-b454-27d62534987e", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "c120bf11efe73f3d878e31bb8ecf2a08e0806e9fa6fb93db79a31d2d20889530", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "23\n. \nSaif MW et al. Dihydropyrimidine dehydrogenase deficiency (GPD) in GI malignancies: experience of 4-years. Pak J Med Sci Q\n2007;23:832-9.\n24\n. \nBoisdron-Celle M et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection\nof dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2007;249:271-82.\n25\n. \nCho HJ et al. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean\npopulation for prediction of 5-fluorouracil-associated toxicity. Ther Drug Monit 2007;29:190-6.\n26\n. \nSalgado J et al. Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and\ntoxicity to capecitabine-raltitrexed in colorectal cancer. Oncol Rep 2007;17:325-8.\n27\n. \nMorel A et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-\nfluorouracil tolerance. Mol Cancer Ther 2006;5:2895-904.\n28\n. \nLargillier R et al. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer Res 2006;12:5496-502.\n29\n. \nSalgueiro N et al. Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal\ncancer patients.", "mimetype": "text/plain", "start_char_idx": 2565, "end_char_idx": 3813, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "92073f68-c3af-4d5b-89c6-ee8a628c1fdd": {"__data__": {"id_": "92073f68-c3af-4d5b-89c6-ee8a628c1fdd", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "23", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "130e7555a70abe4469e920e090af47bb25aea809541373f8ef9d991c843445dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08df4c06-fea7-4612-95d0-c0697ce27a8a", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "2fbfe5a836c8136f89252b8431087df86b63e24d9e7308856d45554b014cf146", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "92a5e5c2-5060-4070-b454-27d62534987e", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "c120bf11efe73f3d878e31bb8ecf2a08e0806e9fa6fb93db79a31d2d20889530", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Genet Med 2004;6:102-7.\n30\n. \nVan Kuilenburg AB et al. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of\npatients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002;12:555-8.\n31\n. \nRaida M et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice\ndonor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res\n2001;7:2832-9.\n32\n. \nvan Kuilenburg AB et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-\nfluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000;6:4705-12.\n33\n. \nSPC\u2019s Fluorouracil PCH, Xeloda, Efudix cr\u00e8me, Fluorouracil (VS) en Xeloda (VS).\nDate 20-11-2017\nDPD genact 0: fluorouracil/capecitabine,systemisch\n2551\nGenetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of fluorouracil/capecitabine to inactive\nmetabolites means that the standard dose is a more than 100-fold overdose.\nRecommendation:\n1\n. \nChoose an alternative\nTegafur is not an alternative, as this is also metabolised by DPD.\n2\n. \nIf an alternative is not possible:\ndetermine the residual DPD activity in mononuclear cells from peripheral blood and adjust the initial dose accordingly.", "mimetype": "text/plain", "start_char_idx": 3814, "end_char_idx": 5210, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9840e038-dfe5-42ce-ae73-339df30d7da7": {"__data__": {"id_": "9840e038-dfe5-42ce-ae73-339df30d7da7", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "23", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "130e7555a70abe4469e920e090af47bb25aea809541373f8ef9d991c843445dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92073f68-c3af-4d5b-89c6-ee8a628c1fdd", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "32ba788b58c256b81671bec0f503d1d74a92cd9e2ac85faed19102cbb98e8f6b", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "92a5e5c2-5060-4070-b454-27d62534987e", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "c120bf11efe73f3d878e31bb8ecf2a08e0806e9fa6fb93db79a31d2d20889530", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "A patient with 0.5% of the normal DPD activity tolerated 0.8% of the standard dose (150 mg capecitabine every 5 days). A\npatient with undetectable DPD activity tolerated 0.43% of the standard dose (150 mg capecitabine every 5 days with every\nthird dose skipped)\nThe average Caucasian DPD activity is 9.9 nmol/hour per mg protein.\nadjust the initial dose based on toxicity and efficacy.", "mimetype": "text/plain", "start_char_idx": 5211, "end_char_idx": 5596, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "fd7b82a0-3f49-46d5-8061-de1089d3af0b": {"__data__": {"id_": "fd7b82a0-3f49-46d5-8061-de1089d3af0b", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "24", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "61296c9fdd3388c1381b9759abe71356ab008a6b1f607cbcc5eb18829f68bd4c", "class_name": "RelatedNodeInfo"}, "5": [{"node_id": "9e95421d-88bb-4add-8c91-1687780045ba", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "1eef1ba1e111548519bc497fb4fa4f50c714e84529bc20dcc719f7b89427decd", "class_name": "RelatedNodeInfo"}, {"node_id": "725c93de-ce80-4519-954e-80e14fc6dd45", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "11b22cb9214deb18e1a593dea6a29bc99e933e2e5f0fb51c19426c35967aab86", "class_name": "RelatedNodeInfo"}, {"node_id": "f2f686b7-45a6-429b-ab92-6fc77b82f66f", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "3c54a970a45a23ee15739aadcb568d7060542560a49cdbbcee6df9e575966d28", "class_name": "RelatedNodeInfo"}, {"node_id": "11430a59-d7ae-4df9-9c97-57014bf0d162", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "0745966d76c25f854e474fc3d10695f574af215f9c44b3694a7748e193e83e38", "class_name": "RelatedNodeInfo"}]}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NOTE: If a patient has two different genetic variations that lead to a non-functional DPD enzyme (e.g. *2A and *13), this\nrecommendation only applies if the variations are on a different allele. If both variations are on the same allele, this patient has gene\nactivity score 1 and the recommendation for that gene activity score should be followed. These two situations can only be distinguished\nby determining the enzyme activity (phenotyping).\nLiterature:\n1\n. \nHenricks LM et al. Treatment algorithm for homozygous or compound heterozygous DPYD variant allele carriers with low-dose\ncapecitabine. JCO Precis Oncol 2017 Oct 8 [Epub ahead of print].\n2\n. \nHenricks LM et al. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine\ndehydrogenase deficiency. Int J Cancer 2017 Sep 20 [Epub ahead of print].\n3\n. \nKodali S et al. Capecitabine-induced severe toxicity secondary to DPD deficiency and successful treatment with low dose 5-\nfluorouracil. J Gastrointest Cancer 2017;48:66-69.\n4\n. \nMeulendijks D et al. Patients homozygous for DPYD c.1129-5923C>G/ haplotype B3 have partial DPD deficiency and require a\ndose reduction when treated with fluoropyrimidines. Cancer Chemother Pharmacol 2016;78:875-80.\n5\n. \nLunenburg CA et al. Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-\ntreated patients. Pharmacogenomics 2016;17:721-9.\n6\n. \nDeenen MJ et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin\nOncol 2016;34:227-34.\n7\n. \nRosmarin D et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the\nQUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 2014; 32:1031-9.\n8\n. \nDeenen MJ et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of\ncapecitabine in advanced colorectal cancer. Clin Cancer Res 2011; 17:3455-68.\n9\n. \nGross E et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-\nrelated toxicity in cancer patients. PLoS ONE 2008;3:e4003.\n10\n. \nBoisdron-Celle M et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection\nof dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2007;249:271-82.\n11\n. \nMorel A et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-\nfluorouracil tolerance. Mol Cancer Ther 2006;5:2895-904.\n12\n. \nVan Kuilenburg AB et al. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of\npatients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002;12:555-8.\n13\n. \nRaida M et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice\ndonor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res\n2001;7:2832-9.\n14\n. \nvan Kuilenburg AB et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-\nfluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000;6:4705-12.\n15\n. \nJohnson MR et al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-\nfluorouracil. Clin Cancer Res 1999;5:2006-11.\n16\n. \nSPC\u2019s Fluorouracil PCH, Xeloda, Efudix cr\u00e8me, Fluorouracil (VS), Xeloda (VS) en Carac cream (VS).\nDate 20-11-2017\nCYP2D6 IM: fluoxetine\n5997\nNO action is needed for this gene-drug interaction.\nThe ratio of fluoxetine/norfluoxetine increases as a result of the reduced activity of CYP2D6. However, this does not affect the sum of\nthe plasma concentrations of the active substances (fluoxetine and norfluoxetine). There is no effect on adverse events or response.\nLiterature:\n1\n. \nGass\u00f3 P et al. Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement\nin children and adolescent patients. Pharmacogenomics J 2014;14:457-62.\n2\n. \nBrandl EJ et al. Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder.\nPharmacogenomics J 2014;14:176-81.\n3\n. \nScordo MG et al. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the\nenantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol 2005;97:296-301.\n4\n. \nLLerena A et al. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-\nstate conditions. Eur J Clin Pharmacol 2004;59:869-73.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 4737, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "9e95421d-88bb-4add-8c91-1687780045ba": {"__data__": {"id_": "9e95421d-88bb-4add-8c91-1687780045ba", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "24", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "61296c9fdd3388c1381b9759abe71356ab008a6b1f607cbcc5eb18829f68bd4c", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "fd7b82a0-3f49-46d5-8061-de1089d3af0b", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "d81f89cdc987be103c0a97d2079af3fb2158301d0c165b425a149a205c99e73c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "NOTE: If a patient has two different genetic variations that lead to a non-functional DPD enzyme (e.g. *2A and *13), this\nrecommendation only applies if the variations are on a different allele. If both variations are on the same allele, this patient has gene\nactivity score 1 and the recommendation for that gene activity score should be followed. These two situations can only be distinguished\nby determining the enzyme activity (phenotyping).\nLiterature:\n1\n. \nHenricks LM et al. Treatment algorithm for homozygous or compound heterozygous DPYD variant allele carriers with low-dose\ncapecitabine. JCO Precis Oncol 2017 Oct 8 [Epub ahead of print].\n2\n. \nHenricks LM et al. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine\ndehydrogenase deficiency. Int J Cancer 2017 Sep 20 [Epub ahead of print].\n3\n. \nKodali S et al. Capecitabine-induced severe toxicity secondary to DPD deficiency and successful treatment with low dose 5-\nfluorouracil. J Gastrointest Cancer 2017;48:66-69.\n4\n. \nMeulendijks D et al. Patients homozygous for DPYD c.1129-5923C>G/ haplotype B3 have partial DPD deficiency and require a\ndose reduction when treated with fluoropyrimidines. Cancer Chemother Pharmacol 2016;78:875-80.\n5\n. \nLunenburg CA et al. Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-\ntreated patients. Pharmacogenomics 2016;17:721-9.\n6\n. \nDeenen MJ et al.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1449, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "725c93de-ce80-4519-954e-80e14fc6dd45": {"__data__": {"id_": "725c93de-ce80-4519-954e-80e14fc6dd45", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "24", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "61296c9fdd3388c1381b9759abe71356ab008a6b1f607cbcc5eb18829f68bd4c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e95421d-88bb-4add-8c91-1687780045ba", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "1eef1ba1e111548519bc497fb4fa4f50c714e84529bc20dcc719f7b89427decd", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "fd7b82a0-3f49-46d5-8061-de1089d3af0b", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "d81f89cdc987be103c0a97d2079af3fb2158301d0c165b425a149a205c99e73c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "6\n. \nDeenen MJ et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin\nOncol 2016;34:227-34.\n7\n. \nRosmarin D et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the\nQUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 2014; 32:1031-9.\n8\n. \nDeenen MJ et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of\ncapecitabine in advanced colorectal cancer. Clin Cancer Res 2011; 17:3455-68.\n9\n. \nGross E et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-\nrelated toxicity in cancer patients. PLoS ONE 2008;3:e4003.\n10\n. \nBoisdron-Celle M et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection\nof dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2007;249:271-82.\n11\n. \nMorel A et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-\nfluorouracil tolerance. Mol Cancer Ther 2006;5:2895-904.\n12\n. \nVan Kuilenburg AB et al. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of\npatients with severe 5-fluorouracil-associated toxicity.", "mimetype": "text/plain", "start_char_idx": 1428, "end_char_idx": 2758, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "f2f686b7-45a6-429b-ab92-6fc77b82f66f": {"__data__": {"id_": "f2f686b7-45a6-429b-ab92-6fc77b82f66f", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "24", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "61296c9fdd3388c1381b9759abe71356ab008a6b1f607cbcc5eb18829f68bd4c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "725c93de-ce80-4519-954e-80e14fc6dd45", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "11b22cb9214deb18e1a593dea6a29bc99e933e2e5f0fb51c19426c35967aab86", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "fd7b82a0-3f49-46d5-8061-de1089d3af0b", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "d81f89cdc987be103c0a97d2079af3fb2158301d0c165b425a149a205c99e73c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Pharmacogenetics 2002;12:555-8.\n13\n. \nRaida M et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice\ndonor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res\n2001;7:2832-9.\n14\n. \nvan Kuilenburg AB et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-\nfluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000;6:4705-12.\n15\n. \nJohnson MR et al. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-\nfluorouracil. Clin Cancer Res 1999;5:2006-11.\n16\n. \nSPC\u2019s Fluorouracil PCH, Xeloda, Efudix cr\u00e8me, Fluorouracil (VS), Xeloda (VS) en Carac cream (VS).\nDate 20-11-2017\nCYP2D6 IM: fluoxetine\n5997\nNO action is needed for this gene-drug interaction.\nThe ratio of fluoxetine/norfluoxetine increases as a result of the reduced activity of CYP2D6. However, this does not affect the sum of\nthe plasma concentrations of the active substances (fluoxetine and norfluoxetine). There is no effect on adverse events or response.\nLiterature:\n1\n. \nGass\u00f3 P et al. Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement\nin children and adolescent patients.", "mimetype": "text/plain", "start_char_idx": 2759, "end_char_idx": 4136, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "11430a59-d7ae-4df9-9c97-57014bf0d162": {"__data__": {"id_": "11430a59-d7ae-4df9-9c97-57014bf0d162", "embedding": null, "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "24", "node_type": "4", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "61296c9fdd3388c1381b9759abe71356ab008a6b1f607cbcc5eb18829f68bd4c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2f686b7-45a6-429b-ab92-6fc77b82f66f", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "3c54a970a45a23ee15739aadcb568d7060542560a49cdbbcee6df9e575966d28", "class_name": "RelatedNodeInfo"}, "4": {"node_id": "fd7b82a0-3f49-46d5-8061-de1089d3af0b", "node_type": "1", "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}, "hash": "d81f89cdc987be103c0a97d2079af3fb2158301d0c165b425a149a205c99e73c", "class_name": "RelatedNodeInfo"}}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "Pharmacogenomics J 2014;14:457-62.\n2\n. \nBrandl EJ et al. Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder.\nPharmacogenomics J 2014;14:176-81.\n3\n. \nScordo MG et al. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the\nenantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol 2005;97:296-301.\n4\n. \nLLerena A et al. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-\nstate conditions. Eur J Clin Pharmacol 2004;59:869-73.", "mimetype": "text/plain", "start_char_idx": 4137, "end_char_idx": 4737, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "496028ea-fb5c-4ebb-a4aa-69ceba3efd3d": {"__data__": {"id_": "496028ea-fb5c-4ebb-a4aa-69ceba3efd3d", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The guidelines for the use of tamoxifen consider genetic factors that can affect its effectiveness. For patients with impaired CYP2D6 activity, an alternative treatment or an increase in tamoxifen dose by a factor of 1.5-2 is recommended. Aromatase inhibitors are suggested for post-menopausal women as an alternative. Co-medication with CYP2D6 inhibitors like paroxetine and fluoxetine should be avoided when using tamoxifen. Studies have shown that genotype-guided dosing can increase active metabolite exposure in patients with reduced CYP2D6 metabolism. For patients with CYP2D6 poor metabolizer phenotype, increasing the dose to 40 mg/day and monitoring endoxifen concentration is recommended to achieve adequate levels. Studies have demonstrated that patients with this phenotype can achieve an adequate endoxifen concentration when the dose is increased to 40-60 mg/day.", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "4f7e5269-b269-4eda-a90c-6d5205e4af93": {"__data__": {"id_": "4f7e5269-b269-4eda-a90c-6d5205e4af93", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The guidelines focus on genetic factors for the use of tamoxifen in breast cancer treatment. Various studies have been conducted to analyze the impact of CYP2D6 genotypes on tamoxifen response and outcomes in breast cancer patients. Recommendations include adjusting tamoxifen doses based on genetic factors to improve treatment efficacy. Aromatase inhibitors are suggested as an alternative for post-menopausal women. Additionally, guidelines for fluorouracil and capecitabine treatment in patients with DPD deficiency are provided, emphasizing the importance of genetic testing to personalize treatment and reduce the risk of severe toxicity.", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "6e139ab4-ebe7-4009-8104-0fb7dda7b16f": {"__data__": {"id_": "6e139ab4-ebe7-4009-8104-0fb7dda7b16f", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The guidelines focus on genetic factors for the use of fluorouracil and capecitabine. Genetic variations can increase the risk of severe toxicity, leading to potentially fatal outcomes. The guidelines recommend starting with a reduced dose of 25%, 50%, or 75% of the standard dose based on specific genetic variations. Adjustment of the initial dose should be guided by toxicity and effectiveness. Tegafur is not recommended as an alternative due to its metabolism by DPD. The guidelines emphasize the importance of distinguishing between different genetic variations to determine the appropriate gene activity score for personalized treatment. Literature references support the recommendations and highlight the significance of genetic markers in predicting toxicity and efficacy of fluorouracil and capecitabine in cancer patients.", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "e965efc3-2349-41d7-842b-76bc2989ec91": {"__data__": {"id_": "e965efc3-2349-41d7-842b-76bc2989ec91", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The guidelines focus on genetic factors for the use of fluorouracil and capecitabine. Various studies have shown the association between genetic variations and severe toxicity in patients receiving these treatments. Recommendations include choosing an alternative treatment if genetic variations are present, adjusting the initial dose based on DPD enzyme activity, and considering individualized therapy based on genetic testing results. The guidelines also highlight the importance of distinguishing between different genetic variations to determine the appropriate course of action. Studies have shown that patients with reduced DPD activity can tolerate lower doses of capecitabine. Overall, the guidelines emphasize the need to consider genetic factors when prescribing fluorouracil and capecitabine to minimize the risk of severe toxicity.", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}, "3da37a02-feca-4116-9666-582f874d56cb": {"__data__": {"id_": "3da37a02-feca-4116-9666-582f874d56cb", "embedding": null, "metadata": {}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {}, "metadata_template": "{key}: {value}", "metadata_separator": "\n", "text": "The guidelines for the use of fluorouracil&capecitabine consider genetic factors, specifically focusing on the dihydropyrimidine dehydrogenase (DPD) gene. Studies have shown a common point mutation in the DPD gene in patients with severe 5-fluorouracil (5-FU)-related toxicity. Clinical implications of DPD deficiency in patients with severe 5-fluorouracil-associated toxicity have also been identified. Additionally, there is information on the influence of CYP2D6 and CYP2C9 gene variants on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients.", "mimetype": "text/plain", "start_char_idx": null, "end_char_idx": null, "metadata_seperator": "\n", "text_template": "{metadata_str}\n\n{content}", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"415b6f71-dfce-48b2-9d09-886ac60be37d": {"doc_hash": "12e2f65a49709251a0f19efb2fe46940a9b61462ad30bb506ebc5160ccd4651c", "ref_doc_id": "16"}, "4d7a83cf-6818-4995-b087-c6500328b6cc": {"doc_hash": "019751c8d2f302ca857042d6b00d58cb890adc18f000afac3fd8ca9f6fc70f74", "ref_doc_id": "16"}, "75545837-636f-40fb-a3ba-7d32cd53b7a8": {"doc_hash": "2c6f2354dcdea396f0338ba1d28914ab25a595fdfb3f942c508f4158e4029a34", "ref_doc_id": "16"}, "2191927a-5564-4bfe-ac51-fdef7371c820": {"doc_hash": "0502ea6b6131ee9dc22dcb9d89103b19969a23f42fee277691867732444b5485", "ref_doc_id": "16"}, "9165a3ad-f0ac-4d02-b76e-7b2ad6075a39": {"doc_hash": "6fa19094be05570294b7d91839e73dca4d275cd56deaf055a7af02ee10919a2d", "ref_doc_id": "16"}, "03b486a0-1625-4a09-b986-23c46f1ac0f4": {"doc_hash": "6b2699f9dda99389b5dc834f678e0bd7b335e4b9e845b8cbd254ceb8eab3dc53", "ref_doc_id": "17"}, "14461f29-2cc7-4f93-8f5a-49fc29f2c123": {"doc_hash": "d1aacfb28e44e702b346507f0402f4a53fd97eb16552c76a1f675c0748151260", "ref_doc_id": "17"}, "708ee684-e806-4b65-88d2-8c3e0ff2fc11": {"doc_hash": "a183eaa04f1d3716dc8d306b7f11507ae8ae2da643d40330a0815a02c1cda5fb", "ref_doc_id": "17"}, "08aa4462-cd86-4356-b37e-35ac92814ae6": {"doc_hash": "884ac6e5963457f3a8ea03ca6d5f84f1aac5a2e1297eca6d6814d6a973000595", "ref_doc_id": "17"}, "3a6c6024-87dc-4714-9e0d-29dfe3921274": {"doc_hash": "8537ae12299429590fb43d89e07c27193d4f9d698f8421632a90d2b7b941e871", "ref_doc_id": "17"}, "fb9a1a99-967f-4e87-818f-0321c337c788": {"doc_hash": "27875d61e477656deefe5cf1d3b6bd2ed4a399b5474a0afdabe4e0f3c2e4e3cb", "ref_doc_id": "18"}, "04b88305-c67b-42a2-85b5-0b782f5b198c": {"doc_hash": "861e5a42202db9cccfd65817c1b03f3d2eab3ed182121b0fa8dcaabb54a8deb4", "ref_doc_id": "18"}, "6a701a8f-e6b0-4f8d-a3d7-6e35518d11b2": {"doc_hash": "39e892fe7c6cc42b7ba804c5b1bc262372463518a27e0b1bd59d2cd8b426f244", "ref_doc_id": "18"}, "a1d653d7-76c9-450c-83d5-b8cace8b2ba1": {"doc_hash": "defeeb5c6452b495b75274981e0d0b81d1688585d09b8fb7d2a8699df15657c1", "ref_doc_id": "18"}, "6113650c-69ea-45cf-916c-c1355374ff25": {"doc_hash": "b1705f98ed4f3a519ecac2a738e337b4f09ed3cd677bd88e787a984257686929", "ref_doc_id": "18"}, "9c3f8a89-7eab-42f2-ad46-7eac6a5e8a5a": {"doc_hash": "6db23416641e461bc4dfa4a04be117660458867c4a2d2f3bae3c66dd32e74bd6", "ref_doc_id": "19"}, "5012c871-a6d4-47f6-bd6c-74f4824a2b18": {"doc_hash": "a46f935119d4d1ddf9d004b3f07cecb72b060dd167f4552bf1e7f2c3fcfcabd3", "ref_doc_id": "19"}, "193ca1aa-5fdf-4adb-9fcc-f8ebe5e2ef23": {"doc_hash": "b6aabc7b26b54124d6be0f7551597e08d06b59381ceee7dccd40526959936e18", "ref_doc_id": "19"}, "9b598374-0d56-439a-8d8e-8cfddf1a1b92": {"doc_hash": "ab234f8961688f14461d534dd1e1753598b429bfc0b241ac7972d2c2547c4d79", "ref_doc_id": "20"}, "94c6984c-a49e-44ab-bdb4-1c06a14fcaa0": {"doc_hash": "90e4ae755b6e6b918dd53ec42f9fa811c672ad96e2be71a73400f1c46defeb91", "ref_doc_id": "20"}, "71e1577f-3c36-424f-8bc2-b71cbba28ae3": {"doc_hash": "7b81803d283427a490eef4d3dfaf76f4d09f5671be549bf9bc7d8f2df52fdbc2", "ref_doc_id": "20"}, "3273f083-db3d-4b38-8667-79c1a5da6848": {"doc_hash": "e5168ff4283e47f0b1e724bce524c482cf48da14be19ea29b26d08a893b851ed", "ref_doc_id": "20"}, "36f34188-c210-4cde-8d5e-4ce823868833": {"doc_hash": "c94e23a701effcb327d74e394f3699e8651b7246f20b51434e79ba5d5aa7e9d6", "ref_doc_id": "21"}, "b44735f9-dcfe-49f4-b843-646890feff8f": {"doc_hash": "6396c4748966077e51508c0a118bebab995c99eb8e2b3c9986342cc9200a315b", "ref_doc_id": "21"}, "a0f5dc73-3e75-4134-83e7-a0060ff196cc": {"doc_hash": "4d6f425df7e2c0ce25f0e9355fc3239ee70b035743d3e551444d5bf3d578b1a8", "ref_doc_id": "21"}, "8c845ae6-8415-4719-8aa3-51143c294121": {"doc_hash": "eada74b526ac178429c528883e34948af0eb9651d2f6e49d604ec0a0003b8573", "ref_doc_id": "21"}, "c5e631f8-577b-4b4b-8b0f-01af4d02907b": {"doc_hash": "5685c7890375b5ef795b3a90607740b7011cda4e111b5cda4af935ad95887034", "ref_doc_id": "22"}, "5a90d14b-2f82-4d64-b597-17d8d3e9dc64": {"doc_hash": "d0717563f0fca678bb9ca1e803cce0df0f7258f2aac532d8784e6ee55038ff6c", "ref_doc_id": "22"}, "bbf28d45-4656-480a-86cb-7cd1882ceb16": {"doc_hash": "5fd0956cefd1be5e703238175695d4dd31e861943b305164de122afc74827cf8", "ref_doc_id": "22"}, "2625ae14-d3f1-44b2-b3a8-62950da83fb4": {"doc_hash": "3bf52428f79f9bbaf54e2402e2d252fe26d4389cae495ab70c6bc84f6b807ade", "ref_doc_id": "22"}, "baf2b098-1a60-492d-a258-05248db633b6": {"doc_hash": "cd0f13930c937805200f9ae318dc527b6e94e5bf4960be3f20634293b76ecb85", "ref_doc_id": "22"}, "92a5e5c2-5060-4070-b454-27d62534987e": {"doc_hash": "c120bf11efe73f3d878e31bb8ecf2a08e0806e9fa6fb93db79a31d2d20889530", "ref_doc_id": "23"}, "916f94a0-3349-48e9-8d9f-5af02adb6617": {"doc_hash": "1489d86af0ba266a38bf3e0136da9172998019bfa73f82572c6ca0992af837d4", "ref_doc_id": "23"}, "cfe5cf7e-aa1c-4371-8bad-53c31945979c": {"doc_hash": "7ceddd79527cde2c72ecb80eb26064b55f645a7f735168b10886e8cf0e5d0905", "ref_doc_id": "23"}, "08df4c06-fea7-4612-95d0-c0697ce27a8a": {"doc_hash": "2fbfe5a836c8136f89252b8431087df86b63e24d9e7308856d45554b014cf146", "ref_doc_id": "23"}, "92073f68-c3af-4d5b-89c6-ee8a628c1fdd": {"doc_hash": "32ba788b58c256b81671bec0f503d1d74a92cd9e2ac85faed19102cbb98e8f6b", "ref_doc_id": "23"}, "9840e038-dfe5-42ce-ae73-339df30d7da7": {"doc_hash": "2777dc9b159b85f7a02f2c910c4a2aa3d00340b7d01a812af1eeb1215bb84e7e", "ref_doc_id": "23"}, "fd7b82a0-3f49-46d5-8061-de1089d3af0b": {"doc_hash": "d81f89cdc987be103c0a97d2079af3fb2158301d0c165b425a149a205c99e73c", "ref_doc_id": "24"}, "9e95421d-88bb-4add-8c91-1687780045ba": {"doc_hash": "1eef1ba1e111548519bc497fb4fa4f50c714e84529bc20dcc719f7b89427decd", "ref_doc_id": "24"}, "725c93de-ce80-4519-954e-80e14fc6dd45": {"doc_hash": "11b22cb9214deb18e1a593dea6a29bc99e933e2e5f0fb51c19426c35967aab86", "ref_doc_id": "24"}, "f2f686b7-45a6-429b-ab92-6fc77b82f66f": {"doc_hash": "3c54a970a45a23ee15739aadcb568d7060542560a49cdbbcee6df9e575966d28", "ref_doc_id": "24"}, "11430a59-d7ae-4df9-9c97-57014bf0d162": {"doc_hash": "0745966d76c25f854e474fc3d10695f574af215f9c44b3694a7748e193e83e38", "ref_doc_id": "24"}, "496028ea-fb5c-4ebb-a4aa-69ceba3efd3d": {"doc_hash": "964641199e0a3161601a5896d55c3d0f73eb17a9b4f4487cca36ff1ed61ebf63"}, "4f7e5269-b269-4eda-a90c-6d5205e4af93": {"doc_hash": "a9b5f921f6e0e5438e6e1f134d6fa8430538451e70b92046c0dc7b6095197546"}, "6e139ab4-ebe7-4009-8104-0fb7dda7b16f": {"doc_hash": "133126e42aaafafe2e01dfcf38db10ff5ebb29e817e1b005d14b6dfdf3b1257d"}, "e965efc3-2349-41d7-842b-76bc2989ec91": {"doc_hash": "a5af9f15663bec0c9963d20234c98c8949d2c97ea3a5b84da127c55f93fff239"}, "3da37a02-feca-4116-9666-582f874d56cb": {"doc_hash": "54448aa8c09e6b644cd5738819b6629627276f2c96646a9fe640c68556e9fdcc"}}, "docstore/ref_doc_info": {"16": {"node_ids": ["415b6f71-dfce-48b2-9d09-886ac60be37d", "4d7a83cf-6818-4995-b087-c6500328b6cc", "75545837-636f-40fb-a3ba-7d32cd53b7a8", "2191927a-5564-4bfe-ac51-fdef7371c820", "9165a3ad-f0ac-4d02-b76e-7b2ad6075a39"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 0, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}}, "17": {"node_ids": ["03b486a0-1625-4a09-b986-23c46f1ac0f4", "14461f29-2cc7-4f93-8f5a-49fc29f2c123", "708ee684-e806-4b65-88d2-8c3e0ff2fc11", "08aa4462-cd86-4356-b37e-35ac92814ae6", "3a6c6024-87dc-4714-9e0d-29dfe3921274"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 1, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}}, "18": {"node_ids": ["fb9a1a99-967f-4e87-818f-0321c337c788", "04b88305-c67b-42a2-85b5-0b782f5b198c", "6a701a8f-e6b0-4f8d-a3d7-6e35518d11b2", "a1d653d7-76c9-450c-83d5-b8cace8b2ba1", "6113650c-69ea-45cf-916c-c1355374ff25"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 2, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}}, "19": {"node_ids": ["9c3f8a89-7eab-42f2-ad46-7eac6a5e8a5a", "5012c871-a6d4-47f6-bd6c-74f4824a2b18", "193ca1aa-5fdf-4adb-9fcc-f8ebe5e2ef23"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/tamoxifen_DPWG_November_2018-1_anticancer-1.pdf", "page": 3, "drug": "tamoxifen", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of tamoxifen"}}, "20": {"node_ids": ["9b598374-0d56-439a-8d8e-8cfddf1a1b92", "94c6984c-a49e-44ab-bdb4-1c06a14fcaa0", "71e1577f-3c36-424f-8bc2-b71cbba28ae3", "3273f083-db3d-4b38-8667-79c1a5da6848"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 0, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}}, "21": {"node_ids": ["36f34188-c210-4cde-8d5e-4ce823868833", "b44735f9-dcfe-49f4-b843-646890feff8f", "a0f5dc73-3e75-4134-83e7-a0060ff196cc", "8c845ae6-8415-4719-8aa3-51143c294121"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 1, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}}, "22": {"node_ids": ["c5e631f8-577b-4b4b-8b0f-01af4d02907b", "5a90d14b-2f82-4d64-b597-17d8d3e9dc64", "bbf28d45-4656-480a-86cb-7cd1882ceb16", "2625ae14-d3f1-44b2-b3a8-62950da83fb4", "baf2b098-1a60-492d-a258-05248db633b6"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 2, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}}, "23": {"node_ids": ["92a5e5c2-5060-4070-b454-27d62534987e", "916f94a0-3349-48e9-8d9f-5af02adb6617", "cfe5cf7e-aa1c-4371-8bad-53c31945979c", "08df4c06-fea7-4612-95d0-c0697ce27a8a", "92073f68-c3af-4d5b-89c6-ee8a628c1fdd", "9840e038-dfe5-42ce-ae73-339df30d7da7"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 3, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}}, "24": {"node_ids": ["fd7b82a0-3f49-46d5-8061-de1089d3af0b", "9e95421d-88bb-4add-8c91-1687780045ba", "725c93de-ce80-4519-954e-80e14fc6dd45", "f2f686b7-45a6-429b-ab92-6fc77b82f66f", "11430a59-d7ae-4df9-9c97-57014bf0d162"], "metadata": {"source": "/storage/home/jyjeon830/data/guidelines/fluorouracil&capecitabine_DPWG_November_2018-1_anticancer.pdf", "page": 4, "drug": "fluorouracil&capecitabine", "document_type": "guideline", "summary": "Guidelines considering genetic factors for the use of fluorouracil&capecitabine"}}}}